Assessing the role of LRP/LR on the viability of pancreatic cancer and neuroblastoma cells through siRNA-mediated LRP/LR down-regulation by Chetty, Carryn Jude
 
 
                
 
 
Assessing the role of LRP/LR on the viability of 
pancreatic cancer and neuroblastoma cells through 
siRNA-mediated LRP/LR down-regulation 
 
 
 
 
 
Dissertation by: Carryn Jude Chetty 
Person number: 363350 
Submitted to: The Faculty of Science, University of the 
Witwatersrand, Johannesburg, in fulfilment of the requirements 
for the degree of Master of Science, 2015 
 
 
DECLARATION 
I, Carryn Jude Chetty (363350), am a student registered for the degree of Master of Science 
in the academic year 2015.  
I hereby declare the following: 
 I am aware that plagiarism is wrong. 
 I confirm that the work submitted for assessment for the above degree is my own 
unaided work except where explicitly indicated otherwise and acknowledged. 
 I have not submitted this work before for any other degree or examination at this or 
any other university. 
 The information used in the dissertation has not been obtained by me while employed 
by, or working under the aegis of, any person or organisation other than the 
university. 
 I have followed the required conventions in referencing the thoughts and ideas of 
others. 
 I understand that the University of the Witwatersrand may take disciplinary action 
against me if there is belief that this is not my own unaided work or that I have failed 
to acknowledge the source of ideas or words in my writing. 
Signature:  
 
Date:  
5/11/2015  
 
 
 
 
 
 
 
 
 
Dedicated to Braxter (28.03.2002 – 
16.08.2012) and Furby (05.02.2005 – 
16.06.2014). 
 Gone but never forgotten. 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Over the decades, cancer has become a global burden with alarmingly high incidence and 
mortality rates in both economically developed and developing countries. Characteristically, 
tumour cells exhibit an over-expression of the 37kDa/67kDa laminin receptor (LRP/LR) in 
comparison to their normal cell counterparts, with this receptor being implicated in several 
tumourigenic processes – importantly for the present study, the maintenance of cellular 
viability and the evasion of apoptosis. This present study aimed to elucidate the role of 
LRP/LR on the cellular viability of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) 
cells. Flow cytometry revealed that both of these tumourigenic cell lines exhibited LRP/LR 
on their surface, with further analysis using median fluorescence intensity values showing 
that IMR-32 cells contain about 70% more cell-surface LRP/LR than AsPC-1 cells. 
Additionally, Western blotting and densitometry suggested that IMR-32 cells contained about 
63% more total LRP/LR than AsPC-1 cells. Western blot analysis also revealed that targeting 
the mRNA of the 37kDa LRP using a LRP-specific siRNA (siRNA-LAMR1) in AsPC-1 and 
IMR-32 cells led to significant down-regulation of 90% and 71% in LRP expression, 
respectively. Consequently, MTT assays showed that LRP knockdown led to reductions of 
82% and 65% in the viability of AsPC-1 and IMR-32 cells, respectively. Moreover, use of an 
alternative LRP-specific siRNA (esiRNA-RPSA) confirmed the specificity and excluded an 
off-target effect of siRNA-LAMR1 for LRP. BrdU assays revealed that knockdown of LRP  
reduced the proliferation of AsPC-1 and IMR-32 cells by 76% and 44%, respectively. 
Confocal microscopy indicated nuclear morphological changes suggestive of apoptosis as the 
form of cell death occuring in both cell lines after LRP down-regulation. This observation 
was confirmed using Annexin-V assays, which revealed that AsPC-1 cells underwent 44% 
more apoptosis than IMR-32 cells post LRP knockdown. Furthermore, caspase-3 activity 
assays revealed that both cell lines experienced apoptotic induction after siRNA-mediated 
down-regulation of LRP. Caspase-8 and -9 activity assays suggested that post LRP 
knockdown, IMR-32 cells undergo apoptosis solely via the extrinsic pathway, whilst AsPC-1 
cells use both the intrinsic and extrinsic apoptotic pathways, possibly through a retaliatory 
feedback loop. Overall, LRP/LR is critical for the maintenance of the tumour cellular 
viability, making the receptor a promising therapeutic target and proposing the potential use 
of siRNA technology for treatment of pancreatic cancer and neuroblastoma. 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer – A worldwide burden 
1.1.1 Epidemiology, diagnosis and treatment 
Over the years, cancer incidence has increased rapidly throughout the world, especially in 
economically developed countries where it has been implicated as the leading cause of 
death
[1]
. Similarly, economically developing countries are also burdened with the disease, 
where it was identified to be the second leading cause of death
[1]
. It is understood that 
majority of cancer types portray a non-discriminative nature and therefore may manifest in 
people of any gender, race, age and economic status
[2]
.  
According to the World Cancer Research Fund (WCRF), 14.1 million incidences of cancer 
were reported worldwide in the year 2012 alone and based on this pattern of occurrence, it 
was estimated that 24 million new diagnoses will be encountered by the year 2035. 
Additionally, the WCRF has identified the 20 most commonly diagnosed cancer types 
globally for the year 2012 (Fig.1). The present study focused on two particular cancer types – 
pancreatic cancer and neuroblastoma – ranked twelfth and seventeenth most commonly 
diagnosed cancer types in the year 2012 contributing to 2.4% and 1.7% of the total number of 
cases diagnosed, respectively (http://www.wcrf.org/cancer_statistics/). These alarming 
statistics indicate the urgency and importance of developing novel therapeutic strategies to 
combat cancer. 
  
Figure 1: Percentage diagnosis of the 20 most common cancer types globally in the year 2012 
(Adopted from: http://www.wcrf.org/cancer_statistics/). 
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Owing to the fact that several cancer types are lifestyle-related, deaths occurring thereof may 
be preventable
[3]
. It is also pivotal that diagnosis occurs early enough to allow cancer cells to 
be rapidly eradicated before metastasis and the formation of secondary, tertiary and 
quaternary tumours occurs – where treatment becomes more difficult and significantly less 
effective
[3]
. 
To date, some of the most common means of cancer diagnosis entail the use of biopsies, 
genetic testing, fluorescent in situ hybridization (FISH), X-rays, ultrasound and magnetic 
resonance imaging (MRI) scans
[4]
. Treatment usually involves chemotherapy, radiation 
therapy, organ transplants or surgery and oftentimes, a combination of these therapeutic 
strategies are used for effective treatment
[5]
. Additionally, deeper insight into the 
characteristic behaviour and functioning of cancerous cells enabled the development of more 
advanced therapeutics such as gene therapy, viral therapy and immunotherapy
[4]
 (Fig.2). It is 
also suggested that certain vaccines may prove to be efficient as therapeutic agents for cancer 
and there is scope for the development of novel vaccines to target different cancer types once 
more knowledge is gained with regards to molecular mechanisms
[4]
. 
 
Figure 2: Commonly-used cancer therapies over the past 100 years 
(http://oncolyticvirus.wordpress.com/2010/03/04/100-years-of-cancer-therapies-and-oncolytic-
viruses).  
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1.1.2 Pancreatic cancer 
1.1.2.1 Characterization 
Pancreatic cancer is ranked amongst the most aggressive cancer types, being the seventh 
highest cause of cancer deaths worldwide, contributing to 6% of total deaths due to cancer 
annually (www.cancerresearchuk.org). It is initiated when cells in the pancreas proliferate 
and multiply uncontrollably, thereby forming a tumour
[6]
. This cancer type is metastatic, 
meaning that it has the ability to invade secondary organs throughout the body
[7]
. Of the 
several types of pancreatic cancer that exist, pancreatic adenocarcinoma (originating in the 
region of the pancreas that is responsible for the production of digestive enzymes) is the most 
common – resulting in about 85% of pancreatic cancer cases[8]. Less aggressive in 
comparison to pancreatic adenocarcinoma are neuroendocrine tumours, which originate in the 
region of the pancreas that produces hormones and are responsible for 1-2 in every 100 
pancreatic cancer cases
[9]
. 
1.1.2.2 Signs, symptoms and risk factors 
Symptoms of pancreatic adenocarcinoma are rare in the early stages of the disease, and 
symptoms that allow the disease to be clearly diagnosed only develop in the advanced 
stages
[8]
. Such symptoms include loss of appetite
[10]
, uncontrolled weight loss
[10]
, darkly-
coloured urine
[11]
, abdominal cramps or pain
[12]
, lightly-coloured stools
[11]
, back pains and 
Jaundice
[12]
. One of the major contributing factors to the aggressiveness of pancreatic cancer 
is the difficulty in detection of the disease due to the late occurrence of symptoms, thereby 
allowing the disease to metastasize to other organs
[13]
. One of the main risk factors for 
pancreatic cancer is age, where the disease is rare before the age of 40 and majority of cases 
are found to be in people exceeding the age of 70
[14]
. Other risk factors include smoking
[15]
, 
some genetic ailments
[16]
, diabetes
[14]
 and obesity
[10]
, with the consumption of certain food 
types such as processed and red meats posing a minor increase in risk
[17, 18]
. 
1.1.2.3 Staging 
Staging of pancreatic cancer usually occurs after a CT scan is performed
[19]
. The most 
commonly used system of staging is the AJCC-UICC (American Joint Committee on Cancer 
– Union for International Cancer Control) system[20]. This system classifies four main stages 
of pancreatic cancer, namely stages T1,T2,T3 and T4 (Fig.3) – based on the size of the 
tumour and metastasis to the lymph nodes and other secondary organs
[20]
. It is understood 
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that at stages T1 and T2, the tumour is considered to be resectable, meaning it can be 
surgically removed
[20]
. At stages T3 and T4, the tumour is either borderline resectable or 
unresectable depending on the degree of metastasis that has occurred
[20]
.  
                                      
                              
Figure 3: The stages of pancreatic cancer. At stages T1 and T2, the tumour is mainly localized in the 
tissues of the pancreas and the tumour is considered to be resectable by surgery. At stages T3 and T4, 
metastasis and distant metastasis occurs and renders the tumour unresectable – particularly when the 
cancer has spread to the lymph nodes (Adopted from: http://www.cancerresearchuk.org/about-
cancer/type/pancreatic-cancer/treatment/the-stages-of-pancreatic-cancer). 
1.1.2.4 Treatment and prevention 
Commonly used treatment strategies for pancreatic cancer include surgery
[21]
, 
chemotherapy
[22]
, radiation therapy
[23]
 and palliative treatments (which treats the symptoms 
of the disease and not the disease-causing mechanisms)
[24]
. Often, a combination of these 
therapies is used in pancreatic cancer treatment
[25]
. It is recommended that regular screening 
should be carried out via the use of MRI imaging and endoscopic ultrasounds in order to 
allow for early detection and diagnosis of pancreatic cancer
[26, 27]
, since surgery is the only 
possible cure for this cancer type
[21]
. Unconfirmed but suggested preventative measures entail 
abstinence from smoking
[28]
, maintenance of a healthy weight
[28]
 and alterations in dietary 
consumption – decreasing red and processed meats[17] and increasing whole grains, 
vegetables and fruits
[29]
.   
T1 T2 
T3 T4 
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1.1.3 Neuroblastoma 
1.1.3.1 Characterization 
Neuroblastoma is widely considered to be the most commonly occurring cancer type during 
infancy – contributing to 6-10% of all known childhood cancers[30, 31]. Moreover, about 50% 
of neuroblastoma cases are prevalent in children below the age of two years old, with an 
annual global mortality rate of 10 per million children within this age group
[30, 31]
.  
Little is known about the causative factors for neuroblastoma and most cases are non-
familial
[32]
. This cancer type is characterized as a neuroendocrine tumour, meaning that it 
may originate in any element of the neural crest within the sympathetic nervous system
[33]
. 
The adrenal glands serve as the most common region of origin of neuroblastoma, evident in 
about 60% of incidences where the disease is widespread and in about 40% of cases where 
the tumour is localized
[34]
. Additionally, the abdomen and the chest have also been implicated 
as regions where neuroblastoma may develop - contributing to about 30% and 19% of all 
neuroblastoma cases, respectively
[34]
. The neck and pelvic regions have also been identified 
as areas in which neuroblastoma may originate, however these regions are much less 
frequently implicated
[34]
. 
1.1.3.2 Signs, symptoms and risk factors 
Early and effective diagnosis of neuroblastoma is an ongoing challenge since initial 
symptoms of the disease are not clearly identifiable and additionally, about 50-60% of 
neuroblastoma cases exhibit metastases which occurs asymptomatically
[34]
. When present, 
some of the more prominent symptoms include pain in the joints, fever, fatigue and loss of 
appetite
[35]
 – however, the location of the primary tumour and regions of metastasis largely 
determine the symptoms that are experienced (Fig.4). Several possible risk factors for 
neuroblastoma development have been investigated but with inconclusive outcomes, parental 
factors such as smoking, excessive consumption of alcohol, exposure to certain chemicals 
during pregnancy as well as the use of hormone therapies and medicinal preparations
[36, 37, 38]
.  
It is noteworthy that neuroblastoma has been categorized into three main risk groups, namely 
low-, intermediate- and high-risk
[39, 40]
. This categorization is based on factors such as age, 
degree of metastasis, and certain genetic and microscopic features of the tumour cells
[39, 40]
. 
Moreover, low-risk neuroblastoma cases are usually effectively treated with surgery, whereas 
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treatment of high-risk neuroblastoma cases poses increasing difficulty even with the most 
advanced therapeutic strategies available
[39, 40]
. 
 
Figure 4: Possible locations of neuroblastoma tumours. The adrenal glands are the most common 
region in which neuroblastoma tumours originate. Tumours may also develop in the spinal region, causing 
inability to stand, walk and crawl. Pallor can be experienced as a result of neuroblastoma tumours that 
infiltrate the bone marrow. Tumours developing in abdominal regions such as the liver and celiac artery 
may lead to constipation and swollen belly. Swelling, bruising and Horner’s syndrome may develop as a 
result of neuroblastoma tumours originating in the bones around the eyes 
(http://www.mitchellhuthfund.org.uk/#!neuroblastoma/c21kz). 
1.1.3.3 Diagnosis 
Among the most common neuroblastoma diagnostic tools is the measurement of 
catecholamine levels in urine, since about 90% of neuroblastoma cases present with increased 
catecholamine levels
[41]
. Other diagnostic methods include the use of microscopic techniques, 
as well as scans – in particular, a mIBG (meta-iodobenzylguanidine) scan[33, 42]. In essence, 
mIBG is an analogue of norepinephrine and can therefore be incorporated into neurons of the 
sympathetic nervous system in place of this neurotransmitter
[42]
. By use of radio-ionization of 
mIBG, about 90-95% of neuroblastoma tumours can be detected 
 [42]
.  
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1.1.3.4 Staging 
Following detection, neuroblastoma is staged according to its location in the body using the 
International Neuroblastoma Staging System (INSS)
[43, 44]
, described in figure 5 below. 
Figure 5: The stages of neuroblastoma. In stage 1, the tumour is localized in the area of origin. In stages 
2a and 2b, the tumour starts to spread unilaterally to the ipsilateral and contralateral lymph nodes. Stage 3 
involves infiltration of the tumour across the midline with or without involvement of regional lymph 
nodes, whilst stage 4 entails dissemination to distant lymph nodes and regions such as the liver, bone and 
bone marrow, amongst others. Stage 4S neuroblastoma occurs only in patients below the age of one year 
old, with dissemination solely limited to the liver, skin or bone marrow 
(http://www.nant.org/Patients_and_Families/neuroblastoma.php). 
1.1.3.5 Treatment 
Early-stage neuroblastoma tumours are often easily and effectively eradicated due to the 
tumour being localized and are therefore curable by surgery alone. In contrast, advanced-
stage neuroblastoma tumours occurring in children older than 18 months old are increasingly 
difficult to treat even with aggressive therapeutic strategies. Treatment is usually 
administered dependent on the risk category, with low-risk neuroblastoma tumours often 
being observed without any treatment or cured solely with surgery – with a success rate of 
about 90%
[44]
. Intermediate-risk neuroblastoma is often treated with a combination of 
chemotherapy and surgery, and this mode of treatment yields a cure rate of about 70-90%
[45]
. 
High-risk neuroblastoma is treated with intensive multimodal therapies – involving 
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surgery
[46]
, radiation and chemotherapy
[46]
, hematopoietic stem cell
[32, 47]
 and bone marrow 
transplants
[47]
, differentiation agents and immunotherapy
[48]
 – with a cure rate of only about 
30%. Gaining insight into causes and prevention of neuroblastoma remains challenging. 
 
1.2 Cancer – A cellular understanding 
1.2.1 Overview of cancer cells 
Cancer can be defined as abnormal cellular growth resulting from the uncontrolled 
proliferation of cells
[49]
 and diminished levels of apoptosis or programmed cell death
[50]
. 
These events may occur as a result of the accumulation of genetic mutations or they may be 
due to the action of several external factors such as tobacco smoking and exposure to 
radiation, amongst others
[51]
. Essentially, tumourigenesis refers to the process of 
transformation of a normal cell to a cancerous state, facilitated by cellular alterations such as 
epigenetic and unstable genetic modifications
[52]
. Critical contributing factors to the process 
of tumourigenic transformation are cellular alterations, collectively termed “the hallmarks of 
cancer”[53] (Fig.6).    
 
Figure 6: The hallmarks of cancer. These six alterations are essential for the transformation of a cell 
from a normal state to a tumourigenic state
[53]
. 
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1.2.2 The hallmarks of cancer 
The transformation of a normal cell to a neoplastic state is a highly complex and specialized 
process, requiring the acquisition of six essential traits (Fig.6) – elaborated on, below. 
1.2.2.1 Self-sufficiency in growth signals 
Often considered to be the most essential capability acquired by tumour cells is the ability of 
these cells to sustain proliferative signalling
[53]
. In contrast to cancerous cells, normal cells 
are able to maintain a state of homeostasis with regards to cell structure, function and 
number. They do this by regulation of the production and release of signals that stimulate 
growth of the cells and additionally, these signals direct entry of cells into the cell cycle as 
well as the progression of these cells through the cell cycle
[53]
.  
Tumour cells, on the other hand, have the ability to facilitate deregulation of these growth 
signals thus compromising the homeostatic balance
[53]
. Both autocrine and paracrine 
signalling mechanisms have been implicated in growth-signal deregulation and the result of 
this is uncontrolled, continuous cell proliferation
[54, 55]
. It is understood that proliferation of 
tumour cells may be sustained due to their potential for growth in the absence of growth 
factors
[54, 55]
. These neoplastic cells have gained the ability to independently produce their 
own growth factors and alternatively, they can also transmit signals that stimulate normal 
cells within the tumour vicinity to supply them with an array of growth factors
[54, 55]
. 
Moreover, somatic mutations in proteins such as B-Raf and PI3-kinase may result in the 
disruption of proper signalling via the MAP-kinase
[56]
 and PI3K
[57, 58]
 signalling pathways, 
respectively – thereby promoting uncontrolled and continued tumour cell proliferation. 
1.2.2.2 Insensitivity to anti-growth signals 
Apart from the sustenance of growth-promoting signals, tumour cells also need to evade 
growth suppression signals in order to continuously grow and proliferate
[53]
. Critical to the 
processes that govern growth suppression is the action of tumour suppressor genes
[53]
. 
Although several tumour suppressors have been found to play various roles in tumour 
inhibition, two key tumour suppressor genes – namely retinoblastoma (RB) and p53 – have 
been identified as critical in the control and governance of cell fate
[53]
.  
The essential function of the RB protein is to govern whether or not a cell qualifies to 
proceed through the cell growth and cell division cycles by integration of and response to 
intracellular and extracellular signals
[59, 60]
. Defective RB proteins therefore allow cancer 
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cells to proliferate uncontrollably due to a lack of proper regulatory functions provided by the 
RB pathway
[60, 61]
. On the other hand, p53 functions to halt tumour progression upon receipt 
of intracellular abnormality and stress signals
[62]
. Essentially, p53 is a pro-apoptotic member 
which responds to excessive damage to the genome and unfavourable cellular conditions by 
induction of apoptosis
[62]
. Tumour cells have the ability to evade the action of p53, thereby 
avoiding apoptosis and allowing sustained proliferation
[62]
.  
 1.2.2.3 Tissue invasion and metastasis 
When a cell undergoes transformation from a normal to a neoplastic state, it acquires the 
potential to alter the expression of certain molecules
[53]
. Particularly, cell-cell adhesion 
molecules (CAMs) such as E-cadherin have been found to be selectively down-regulated in 
tumour cells
[63]
. This is because E-cadherin facilitates the formation of sheets of epithelial 
cells and is able to keep the cells within these sheets in a quiescent state, thus down-
regulating the expression of this molecule avails cells to undergo tumourigenic 
transformation
[63]
. Conversely, specific proteases such as collagenases are selectively up-
regulated in tumour cells
[64]
. This up-regulation promotes the degradation of the extracellular 
matrix (ECM), allowing cancerous cells to migrate to and invade secondary organs via basal 
lamina degradation
[64]
. 
 1.2.2.4 Limitless replicative potential 
It is widely understood that normal cells are only able to undergo a limited number of growth 
and division cycles. In contrast, tumourigenic cells gain the ability to go through limitless 
cycles of growth and division – a phenomenon known as immortalization[53]. Extensive 
evidence suggests a key role for telomeres in the facilitation of immortalization
[65]
. Telomeres 
comprise several tandem repeats and they are responsible for protecting the ends of 
chromosomes from DNA damage
[65]
. Telomerase is a DNA polymerase enzyme that is 
responsible for the addition of these telomere repeats to the ends of chromosomes, thereby 
preventing DNA damage from occurring
[65, 66]
.  Moreover, the length of telomeric DNA 
governs the number of replicative cycles a cell can go through before degradation occurs
[65]
. 
Therefore, cancerous cells exhibit an up-regulation of telomerase expression in comparison to 
normal cells, thus preventing telomere shortening and allowing cells to continually proliferate 
by avoiding senescence and apoptosis
[65, 66]
.   
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1.2.2.5 Sustained angiogenesis 
Similar to normal cells, neoplastic cells require a sustained source of oxygen, nutrients and 
blood in order for their growth and survival
[53, 67]
. Additionally, tumour cells also require a 
means of removal of carbon dioxide and metabolic wastes
[53, 67]
. These requirements are 
achieved in tumour cells via the deregulated expression of an angiogenic inducer known as 
vascular endothelial growth factor (VEGF)
[68]
. VEGF assists with the initiation and 
promotion of blood vessel formation, thus creating the vasculature required for the tumour to 
acquire nutrients and oxygen and also for waste disposal purposes
[69]
. 
1.2.2.6 Evading apoptosis 
Apoptosis is a mechanism used to induce cell death in response to cellular stress and damage 
to DNA, thereby maintaining the homeostatic balance within the cellular environment
[70]
. 
However, tumour cells are able to evade the process of apoptosis and in this way, the tumour 
is able to proliferate and progress
[70]
. As previously described, the loss of or the deregulated 
expression of the p53 tumour suppressor enables cancerous cells to avoid undergoing the 
process of apoptosis and proliferate uncontrollably to form aggressive tumours
[62]
. 
Additionally, tumourigenic cells up-regulate the expression of certain anti-apoptotic factors 
and down-regulate the expression of pro-apoptotic factors in order to evade apoptosis
[71,72]
. 
Essentially, the evasion of apoptosis has been implicated as a major contributing factor in the 
aggressiveness of an array of cancer types
[53]
, thus it is essential to target the mechanisms that 
govern this hallmark with regards to cancer therapeutics – this being central to the present 
study. 
1.2.3 Apoptosis 
This form of cell death was first described in the early 1800’s by Carl Vogt, however the term 
‘apoptosis’ came into effect only in the 1970’s – named by John Kerr[73]. Apoptosis is now 
understood to be a process of well-ordered, physiological programmed cell death that serves 
essential functions in embryonic development and the maintenance of tissue homeostasis
[50]
. 
In contrast to apoptosis is a form of catastrophic, non-programmed cell death known as 
necrosis
[50]
. Apoptosis is a highly-regulated and important process from infancy throughout 
adulthood, but deregulation of this process often occurs and may lead to detrimental 
conditions such as autoimmune diseases
[74]
, AIDS
[75]
, neurodegenerative disorders
[76]
, and 
cancer
[50]
 – the latter being the focus of the present study. 
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Apoptotic induction can be triggered by external stimuli such as oxidative stress, and also by 
internal stimuli such as DNA damage
[50]
. This induction may result in two types of cellular 
changes: 1) changes in cellular morphology and 2) biochemical alterations
[77]
 (Fig.7). 
Morphological changes occurring during early apoptosis include DNA fragmentation and 
condensation of chromatin, whilst late apoptosis exhibits changes such as membrane 
blebbing, diminished membrane integrity and alterations in the structure of cytoplasmic 
organelles
[77]
. Biochemical alterations to the apoptotic cell include activation of caspases, 
breakdown of DNA and protein, and membrane changes leading to phagocytosis
[78]
. Loss of 
membrane integrity as the cell progresses from an early to a late apoptotic phase causes 
cellular contents to be packed into apoptotic bodies, thereby enabling phagocytosis of dead 
cells by macrophages without harming other cells
[78]
.  
    
Figure 7: Morphological and biochemical alterations in cells undergoing apoptosis. Upon initiation of 
apoptosis, cell shrinkage and subsequent DNA fragmentation occurs. This is followed by membrane 
blebbing, which occurs at later stages of apoptosis and triggers exposure of phosphatidylserine (PS) on the 
outer cell membrane via a “flipping-out” process. This enables the recognition of dead cells by 
macrophages, allowing phagocytosis of the resultant apoptotic bodies 
(http://www.buzzlw.com/articles/how-do-cells-commit-suicide.html). 
The process of apoptosis is largely dependent on caspases, which are proteases that 
specifically function as initiators as well as executioners of apoptosis
[79]
. This family of 
proteases is abundant, but pivotal to the mechanism of apoptosis are caspases 8, 9 and 10, 
serving as initiator caspases, and also caspases 3, 6 and 7, functioning as effector caspases
[79]
. 
When synthesized, caspases are inactive and may be activated either by a process of 
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proteolysis or by transactivation as a result of association with other caspases
[79]
. Two main 
pathways that lead to the activation of caspases have been identified, namely the intrinsic 
(mitochondrial) pathway and the extrinsic (death receptor) pathway
[50]
 (Fig.8). Both of these 
pathways are elaborated on, below.  
 1.2.3.1 Intrinsic (mitochondrial-dependent) pathway 
The mitochondrial-dependent pathway (Fig.8) can be activated by both internal and external 
death signals
[80]
. Internal stimuli originate inside the cell and include DNA damage, hypoxia, 
chemotherapeutic drugs, oxidative stress and high cytosolic concentrations of calcium 
ions
[80]
. External stimuli that can trigger this pathway mainly comprise of cell death signals 
from the death receptor pathway
[80]
. Regardless of the stimulus, this pathway is permitted to 
take place due to mitochondrial membranes exhibiting an increase in permeability
[81]
. 
Another major contributing factor to the occurrence of the intrinsic pathway is the release of 
pro-apoptotic members, in particular cytochrome-c, from the mitochondria into the 
cytosol
[81]
. In addition to cytochrome-c, mitochondrial release of apoptotic factors such as 
Smac, DIABLO, HtrA2 and apoptosis-inducing factor (AIF) also occurs
[82]
. 
Regulation of the mitochondrial-dependent pathway occurs via the action of the Bcl-2 protein 
family
[83]
. The balance between expression of pro-apoptotic Bcl-2 proteins (Bid, Bik, Bak, 
Bax, Bad, Bim, Bcl-Xs and Hrk) and anti-apoptotic Bcl-2 proteins (Bfl-1, Bcl-2, Bcl-XL, Bcl-
W and Mcl-1) facilitates apoptotic regulation by promoting and inhibiting the release of 
cytochrome-c from the mitochondria, respectively
[84]
. Once present in the cytosol, 
cytochrome-c interacts with a monomeric molecule known as apoptotic protease activating 
factor-1 (Apaf-1)
[82]
. This molecule then undergoes a conformational change followed by 
oligomerisation in the presence of ATP, subsequently resulting in procaspase-9 recruitment 
and apoptosome formation
[82]
. Within the apoptosome, procaspase-9 molecules become 
activated to caspase-9 molecules and this causes subsequent activation of procaspase-3 to 
caspase-3 molecules
[85]
. It is these active caspase-3 molecules that initiate downstream 
processes that ultimately lead to cell death
[85]
. 
 1.2.3.2 Extrinsic (death receptor-mediated) pathway 
The death receptor-mediated pathway (Fig.8) is initiated when specific cell surface receptors 
called death receptors become activated upon the binding of their respective death ligands
[78]
. 
It is understood that the afore-mentioned death receptors form part of the tumour necrosis 
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factor receptor (TNFR) superfamily, and such death receptors include TNFR-1 and 
Fas/CD95
[78]
. A characteristic feature of death receptors is that they contain a cytosolic death 
domain (DD)
[86]
. 
Binding of the Fas ligand to the Fas receptor promotes the association of the Fas-associated 
death domain (FADD) proteins with Fas via a process of receptor trimerization
[79]
. Moreover, 
FADD also contains a death effector domain (DED) which is able to recruit and interact with 
procaspase-8 through DED-DED interactions – subsequently forming a death induced 
signalling complex (DISC)
[87]
. Procaspase-8 molecules become concentrated within the DISC 
and transactivation of these molecules can occur seeing that they are in close proximity with 
each other
[80]
. In this way, active caspase-8 molecules are produced and can therefore cleave 
inactive procaspase-3 molecules to form active caspase-3
[80]
. Ultimately, active caspase-3 
facilitates the cleavage of certain downstream substrates in order to cause cell death
[80]
. 
     
Figure 8: The two main apoptotic pathways occurring in mammalian cells. A) The intrinsic pathway 
relies on the mitochondrial release of cytochrome-c into the cytosol in response to either internal or 
external stimuli. Interactions between cytochrome-c and Apaf-1 lead to subsequent recruitment of 
procaspase-9 molecules, ultimately forming the apoptosome. Active caspase-9 molecules are formed 
within the apoptosome and facilitate the activation of procaspase-3 molecules to active caspase-3, resulting 
in downstream events leading to cell death. B) The extrinsic pathway is initiated when Fas binds to and 
interacts with the FADD proteins of the Fas receptor via a process of receptor trimerization. The DED of 
FADD associates with the DED of procaspase-8, forming a complex called DISC. DISC allows the 
transactivation of procaspase-8 molecules in order to form active caspase-8 molecules – thereby assisting 
in downstream activation of caspase-3 and ultimately causing cell death
[88]
.  
A) B) 
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It is noteworthy that although these apoptotic pathways are highly controlled and regulated, 
dysregulation of these may occur and result in several conditions such as neurodegenerative 
disorders
[89]
 and cancer
[90]
. In contrast to neurodegenerative disorders, cancer exhibits 
diminished levels of apoptosis which subsequently facilitates tumourigenesis. The present 
study targets this property of cancerous cells, thus an elaboration on the association between 
the lack of apoptotic cell death and enhancement of tumour progression follows. 
1.2.4 Relationship between apoptosis and cellular proliferation 
By definition, cellular proliferation describes a type of cell division that yields an increase in 
cell number
[91]
 (Fig.9). Conversely, apoptosis is responsible for the eradication of damaged 
cells, thus leading to a reduction in cell number
[92]
. It is therefore evident that these two 
processes are closely related so as to maintain tissue homeostasis by tightly regulating cell 
numbers.  
 
Figure 9: Comparison between normal and tumourigenic cell division. Normal cell division occurs as 
a result of non-oncogenic mutations that facilitate apoptotic induction in damaged cells. Alternatively, 
tumourigenic cell division is assisted by oncogenic mutations that result in uncontrolled cellular growth 
and proliferation (Adapted from: http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer). 
 
Non-oncogenic 
mutations 
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Oncogenic 
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In order for an organism to grow and function properly, the cell cycle (Fig.10) needs to be 
adequately completed. Essentially, chromosome duplication and replication in daughter cells 
are key processes that are responsible for the growth of cells
[93]
. These processes are highly 
regulated by the cell cycle
[93]
. Additionally, cyclin-dependent kinases (CDK’s) have been 
identified as critical proteins that drive the progression of the cell through the stages of the 
cell cycle
[93]
. 
 
Figure 10: Stages of the cell cycle. Phase G0 (Gap 0) is the stage at which cells are quiescent but 
metabolically active. Certain growth factors and nutrients serve as extracellular signals which can 
stimulate entry of inactive quiescent cells into Phase G1 (Gap 1) and subsequent progression to the S-
phase. During the S-phase, cells undergo DNA replication which permits entry into the G2 (Gap 2) phase – 
in which cells increase in size and synthesize proteins required for the M-phase. The M-phase involves 
mitotic duplication of cells to form identical daughter cells. G1-S and G2-M serve as checkpoints to ensure 
the orderly progression of cells through critical phases of the cell cycle (Adapted from: http: 
//www.bdbiosciences.com/research/apoptosis/analysis/index.jsp.)  
An array of genes have been found to regulate the cell cycle and importantly, many of these 
genes have also been implicated in apoptotic regulation
[92]
. Such genes include c-myc, c-jun, 
c-fos and p53
[92]
. Pivotal to the relationship between apoptotic cell death and cellular 
proliferation is p53
[79]
 (Fig.11), whose essential role is the maintenance of genome integrity 
by examination of cells in the G1-S and G2-M checkpoints of the cell cycle
[94]
. This is done 
G1-S 
checkpoint 
G2-M 
checkpoint 
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in order to detect unfavourable genome alterations, thus halting the progression of aberrant 
cells through the cell cycle
[94]
. Consequently, mutations in p53 impedes proper functioning of 
the G1-S and G2-M checkpoints, thereby allowing the survival and uncontrolled proliferation 
of damaged cells – ultimately promoting tumour formation[94].  
 
                                                                                                       Apoptotic stimulus 
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                                                                                                               Apaf-1 
                                                                                                             Caspase 9 
 
                                                                                                              Caspase 3 
   
 
 
Figure 11: Role of p53 in the induction of apoptosis. Upon detection of an apoptotic stimulus, p53 
becomes activated and causes subsequent activation of Bax – a pro-apototic gene. This causes activation of 
Smac via Bcl-2 inhibition and consequently results in the inactivation of inhibitors of apoptosis (IAPs). 
Cytochrome-c, a pro-apoptotic molecule, is released from the mitochondrion upon detection of an 
apoptotic signal. Interactions between Smac and cytochrome-c facilitate apoptotic induction via the 
intrinsic pathway. Mutations in p53 prevent this apoptotic induction process from taking place and thereby 
promotes the tumourigenic phenotype (Adopted from: http://www.sigmaaldrich.com/content/dam/sigma-
aldrich/life-science/cell-signalling-and/migratecellsignal2/ ATM-p53_signalling_pathway.jpg.) 
1.2.5 Role of apoptosis in tumour progression 
As previously mentioned, genes are pivotal to the occurrence and regulation of apoptosis, 
thus making this process of cell death highly susceptible to genetic mutations. The aberrant 
p53 
Mitochondrion 
APOPTOSIS 
 Bax 
 IAPs 
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expression of certain genes is implicated in disruptions to the homeostatic balance, therefore 
affording cells the ability to proliferate in an uncontrolled manner
[53]
. Such genes are 
discussed below. 
 1.2.5.1 Bcl-2 protein family 
Comprising of both pro- and anti-apoptotic proteins, this family of proteins plays a critical 
role in apoptotic regulation
[95]
. However, several cancers exhibit deregulated expression of 
the genes encoding for these proteins
[50]
. Over-expression of Bcl-2 has been shown to 
contribute to the evasion of apoptosis by breast
[96]
, prostate
[97]
 and brain
[96]
 cancers. Studies 
have additionally suggested that cells that over-express Bcl-2 proteins gain a phenotype that 
allows them to become multi-drug resistant, thereby aiding cells in tumour formation
[98]
. 
 1.2.5.2 Tumour necrosis factor (TNF) protein family 
Death receptor-mediated apoptosis is often avoided by tumour cells as a result of the 
acquisition of resistance to key components that induce this apoptotic pathway. Aberrations 
causing the over-expression of genes coding for inhibitors of the extrinsic pathway, such as 
the caspase homolog cFlip, have been identified as contributing factors to the occurrence of 
several types of cancer
[99]
. Such inhibitors operate by competing with caspases for binding to 
FADD, subsequently hampering apoptosis and resulting in the formation of a tumour that is 
Fas-resistant
[99]
. This resistance is beneficial to tumours by allowing them to evade apoptosis 
in the presence of the Fas ligand (a major protein of the TNF family)
[99]
 and additionally, Fas-
resistance enhances tumour progression by the expression of Fas ligand on the surface of 
tumourigenic cells – without causing damage to the cells themselves[100]. 
 1.2.5.3 Inhibitor of apoptosis (IAP) protein family 
The IAP family consists of several proteins such as Survivin, XIAP, cIAP1 and cIAP2 – all 
of which have been suggested to interact with specific caspases and inhibit their pro-
apoptotic function
[101]
. Moreover, IAP proteins interact with HtrA2 and Smac/DIABLO, thus 
leading to caspase activation and the induction of pro-apoptotic events due to the prevention 
of proper interactions between IAPs and caspases
[101]
. To date, much is still unknown about 
the expression of genes encoding IAPs in cancerous cells, but the deregulation of this 
expression has been implicated in several cancers. Particularly, the over-expression of IAPs 
such as Apollon has been identified in gliomas
[102]
, whilst XIAP and Survivin have been 
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found to exhibit over-expression in non-small cell lung cancer
[103]
. Additionally, Livin is an 
IAP that shows characteristic over-expression in melanoma cells
[104]
.   
It is critically important to note that all of the afore-mentioned processes that govern proper 
cell functioning, such as apoptosis and cell proliferation, do not occur in isolation but rather 
depend closely on the interaction of cells with their environment – the extracellular matrix 
(ECM). 
1.2.6 The extracellular matrix (ECM) 
Apart from cell-cell associations, cells also communicate via interactions with their 
surrounding environment –known as the extracellular matrix or ECM[105] (Fig.12). This 
matrix is complex in nature and serves the principal function of supplying and co-ordinating 
signals that: regulate proper cell functioning, direct and control cell migration, ensure the 
adequate receptor-mediated provision of nutrients required by the cell, and facilitate cell 
contacts
[106]
. Structurally, two essential domains form the ECM, namely: 1) the basement 
membrane and 2) the matrix (condensed) layer
[105]
. The latter is composed of proteoglycans,  
matrix metalloproteinases (MMPs), and an array of glycoproteins such as fibronectins, 
integrins, collagens, elastin, and pivotal to the present study, the family of laminins
[105, 106]
. 
 
Figure 12: The extracellular matrix. The two main domains that make up the ECM are the basement 
membrane and the condensed stromal matrix layer. Laminins form an essential component of the basement 
membrane, whilst MMPs and several glycoproteins such as fibronectins, laminins, collagens, elastin, and 
integrins contribute to the composition of the stromal matrix (http://www.boundless.com/biology/) 
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1.2.6.1 The family of laminins 
 Laminins are glycoproteins that play a major role in the formation of the ECM
[106]
. 
Essentially, laminins are composed of three types of chains namely the α-, β- and γ-chains 
(Fig.13), which are joined together by disulphide bonds and are differentially assembled in 
order to form 17 heterotrimeric laminin isoforms
[107]
. These heterotrimers comprise several 
sites for binding of ECM components such as proteoglycans, integrins, collagen and 
entactin
[107]
. Additionally, there is also a binding site for other molecules of laminin, to allow 
for the formation of basal lamina sheets
[107]
. Functionally, laminin has been identified to play 
key roles in processes such as cell migration
[108]
, adhesion
[109]
, neurite outgrowth
[110]
, cell 
differentiation and proliferation
[111]
, as well as tumourigenic processes such as metastasis and 
angiogenesis
[112]
. Moreover, laminin also contains sites that allow for binding to cell surface 
receptors
[112]
. One such receptor – and of particular importance to the present study – is the 
37kDa/67kDa non-integrin laminin receptor precursor/ high-affinity laminin receptor 
(LRP/LR)
[113]
. 
 
Figure 13: The structure of laminin. The α-, β- and γ-chains of laminin are stabilized by interchain 
disulphide bonds. Laminin contains binding sites for several ECM molecules such as collagen IV, entactin 
and heparin, and also binds an array of cell surface receptors in order to carry out its many functions 
(http://themeekgroup.com/Christian/laminin.htm.) 
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1.2.7 The 37kDa/67kDa laminin receptor precursor/laminin receptor (LRP/LR) 
LRP/LR is a major extracellular matrix receptor that was initially isolated and purified from 
normal muscle cells
[114]
, murine melanoma
[115]
 and human breast carcinoma cells
[116]
 in the 
year 1983. This non-integrin laminin receptor was shown to have an approximate molecular 
mass of 67kDa and exhibited high specificity and affinity for binding to laminins, in 
particular laminin-1
[117]
. It was also discovered that the mRNA that encodes for this 67kDa 
laminin receptor (LR) results in the formation of a protein with a length of 295 amino acids 
and an approximate molecular mass of 37kDa
[118, 119]
. This protein was then deemed as the 
precursor of the mature 67kDa laminin receptor, and consequently named the 37kDa laminin 
receptor precursor (LRP)
[118]
. To date, the precise mechanism by which the 37kDa LRP 
forms the 67kDa LR has not been elucidated. Early studies speculated that this mechanism 
may entail a process of homodimerization that occurs through certain post-translational 
modifications
[118]
, however this theory was later disproved when a yeast two hybrid study 
showed failure of LRP to interact with itself and dimerize
[120]
. Other studies suggest that fatty 
acylation by fatty acids such as oleate, stearate and palmitate may be the key modification 
that results in the maturation of the 37kDa LRP into the 67kDa LR form
[119]
. More recent 
evidence has proposed that LRP is a target for small ubiquitin-like modifier (SUMO) 
proteins, which are 8-14kDa in size and have the potential to form oligomeric chains
[121]
. 
Thus, it is suggested that SUMOylation of LRP may be the modification that results in the 
maturation of 37kDa LRP into 67kDa LR
[122]
. 
It is known that LRP/LR (Fig.14) is predominantly found as a transmembrane receptor, 
particularly a type II transmembrane receptor
[113]
. In this location, it plays physiological roles 
in processes such as cellular adhesion, migration, proliferation, and the maintenance of 
cellular viability
[113]
. LRP/LR knockdown studies have also suggested physiological 
functions of this receptor in the cell cycle
[123]
, protein synthesis
[124]
 and processing of 
ribosomal RNA
[125]
. Additionally, this receptor localises in the cytosol
[126]
 and the nucleus
[127]
 
– facilitating translational processes and the maintenance of nuclear structures, respectively. 
LRP/LR has also been identified in the perinuclear region
[127]
. As previously mentioned, 
laminin-1 binds to LRP/LR and this binding occurs at three distinct sites within the C-
terminus of the receptor: 1) amino acid residues 161-180
[128]
, 2) amino acid residues 205-
229
[128]
, and 3) most C-terminal 53 residues
[129]
. The receptor also has binding sites for 
viruses
[130]
, elastin
[131]
, carbohydrates
[131]
, infectious as well as non-infectious prion 
proteins
[131, 132]
, heparin
[131]
, and immunoglobulin G antibodies
[131]
.  
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Numerous studies have implicated LRP/LR as a key contributor to the pathogenesis of certain 
viral and bacterial infections
[130]
, prion-protein related diseases such as Transmissable 
Spongiform Encephalopathies
[133]
, neurodegenerative diseases such as Alzheimer’s 
disease
[134, 135]
, and several cancer types – the latter being of importance to the present study. 
Importantly, an array of cancer cells have exhibited an over-expression of LRP/LR in 
comparison to their normal counterparts, thereby suggesting that this receptor plays a role in 
the processes leading to tumour formation and progression. 
 
Figure 14: The 37kDa/67kDa laminin receptor precursor/laminin receptor (LRP/LR). This 
transmembrane receptor is 295 amino acids in length and comprises three main domains: 1) The N-
terminal intracellular cytosolic domain (blue), 2) The transmembrane domain (red) and 3) The C-terminal 
extracellular domain (purple). The C-terminal domain contains sites for binding of substrates such as 
laminin-1, elastin, heparin, carbohydrates, prion proteins and IgG antibodies
[136]
.  
 
1.2.8 Involvement of LRP/LR in tumour progression 
In contrast to normal cells, several tumourigenic cell lines arising from lung
[137]
, colon
[138]
, 
liver
[139]
, gastric
[140]
, prostate
[141]
, cervical
[142]
, ovarian
[143]
, uterine
[144]
, leukaemia
[145]
 and 
breast
[146]
 cancers have all exhibited up-regulated LRP/LR expression (Fig.15A). The exact 
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mechanism that contributes to the over-expression of LRP/LR in cancer cells when compared 
to normal cells is not fully understood. However, numerous studies have analysed the effects 
of this over-expression and have suggested that tumour progression is promoted via the 
action of LRP/LR-mediated enhancement of metastasis, angiogenic induction, and apoptotic 
evasion
[112]
. 
 1.2.8.1 LRP/LR and metastasis 
As previously described, LRP/LR has a high affinity for binding to laminin-1
[117, 118]
. This 
LRP/LR-laminin-1 interaction has been found to play a crucial role in promoting tumour 
metastasis
[146,147]
 (Fig.15B). Particularly, tumourigenic cells possess increased levels of 
LRP/LR which – upon tumour cell adhesion - interacts with laminin-1 found in the basement 
membrane
[146]
. This interaction triggers subsequent activation of type IV collagenase 
enzymes that facilitate the degradation of type IV collagen within the basement 
membrane
[148]
. Tumour cells are then permitted to invade the stroma, migrate to distant 
organs via the bloodstream, and initiate the formation of secondary tumours at these distal 
sites
[148]
. Two key events involved in metastasis are adhesion and invasion, and the LRP/LR-
laminin-1 interaction has been implicated in the enhancement of both of these events
[148]
. 
Recent studies have shown that fibrosarcoma
[149]
, lung
[150]
, cervical
[150]
, colon
[150]
, 
prostate
[150]
, breast
[151]
, oesophageal
[151]
 and liver
[139]
 cancers all exhibit increased levels of 
LRP/LR and thus increased occurrence of the LRP/LR-laminin-1 interaction. Moreover, 
blockage of this interaction by use of anti-LRP/LR specific antibody IgG1-iS18 resulted in 
diminished levels of adhesion and invasion (Fig.15B)
[139,150,151]
. Therefore, it is evident that 
LRP/LR is crucial for metastatic processes and is a promising target for metastatic cancer 
therapeutics.  
1.2.8.2 LRP/LR and angiogenic induction 
Angiogenesis can be described as a process that entails new blood vessel formation from pre-
existing capillaries
[122]
. This process is critical in embryonic development, growth of tissues, 
wound healing, vascular remodelling, and the menstrual cycle
[153]
. Angiogenesis is able to 
assist with the afore-mentioned processes by providing nutrients and oxygen to the cells that 
require them
[153]
. Normal, healthy individuals display tightly regulated angiogenesis. 
However, dysregulation of angiogenesis has been observed in several conditions such as limb 
disease, rheumatoid arthritis and importantly, growth and metastasis of tumour cells
[154]
. In 
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the case of tumour development, angiogenesis involves the formation of tubular structures 
that permit tumour cells to migrate to distant sites and initiate metastasis at those sites
[153]
. 
Moreover, tumour angiogenesis provides a means by which tumour cells can gain oxygen and 
essential nutrients to facilitate and sustain their growth
[153]
. 
As previously described, the binding of LRP/LR on the cell surface to laminin-1 in the 
basement membrane leads to proteolytic activation that subsequently results in degradation of 
the basement membrane
[148]
. This process of cell-ECM interactions and the resultant 
membrane degradation has been identified as a crucial step in the formation of angiogenic 
tubular structures
[152]
, thus probing research into the involvement of LRP/LR in tumour 
angiogenesis. A recent study showed that anti-LRP/LR specific antibody W3 significantly 
impeded tube formation in human umbilical vein endothelial cells (HUVEC’s), thus 
confirming that LRP/LR does indeed play an important role in the process of 
angiogenesis
[155]
 (Fig.15C). 
 1.2.8.3 LRP/LR and evasion of apoptosis 
As previously mentioned, LRP/LR plays a role in the maintenance of cellular viability. 
Specifically, studies have shown that LRP/LR maintains the viability of yeast cells through 
the ribosomal processing and maturation
[156]
. Additionally, studies have proposed that 
LRP/LR maintains the viability of mammalian cells through the up-regulation of certain 
signalling cascades and also through interactions with Midkine – a growth factor that 
enhances cell migration and promotes cellular proliferation and survival
[127]
. Essentially, 
Midkine has been suggested to assist LRP/LR with binding to the nuclear envelope and 
chromatin in order to stabilize chromosomes, thereby aiding in the maintenance of cellular 
viability
[127]
. 
The up-regulated expression of LRP/LR in tumourigenic cells contributes to the maintenance 
of the viability of such cells. Additionally, it is suggested that LRP/LR facilitates tumour 
enhancement and progression by promoting apoptotic evasion
[157]
. The role played by 
LRP/LR in the inhibition of apoptosis has been confirmed by a study involving the use of 
small-interfering RNAs (siRNAs) directed towards the mRNA of the 37kDa LRP in  liver 
(Hep3b) cancer cells, which led to apoptotic induction as a result of siRNA-mediated 
knockdown of LRP expression
[157]
. More recent studies made use of siRNA-LAMR1 to 
down-regulate LRP expression in cervical (HeLa)
[158]
, lung (A549)
[158]
, breast (MCF-7 and 
MDA-MB 231)
[159]
 and oesophageal (WHCO1)
[159]
 cancer cells, and it was observed that 
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LRP down-regulation induced apoptosis in these two cancerous cell lines (Fig.15D). These 
findings affirm the critical role played by LRP/LR in the maintenance of cellular viability and 
therefore deems this receptor as a potential therapeutic target for cancer treatment.  
The mechanism of siRNA action is discussed in section 1.2.9 below. 
  
Figure 15: The role of the 37kDa/67kDa laminin receptor (LRP/LR) in tumourigenesis. A) Several 
types of cancerous cells exhibit higher levels of LRP/LR in comparison to their normal counterparts. B) 
Up-regulated LRP/LR expression in tumour cells facilitates more binding of the receptor to laminin-1 in 
the basement membrane (adhesion), leading to activation of type IV collagenase which triggers the 
degradation of type IV collagen in the basement membrane – thereby allowing tumour cells to invade 
organs (invasion). Anti-LRP/LR specific antibody IgG1-iS18 blocks the LRP/LR-laminin-1 interaction, 
thus impeding adhesion and invasion – the key events in metastasis. C) Increased levels of LRP expression 
have been implicated in the formation of endothelial tubes, thus suggesting that the receptor plays a pivotal 
role in tumour angiogenesis. Use of anti-LRP/LR specific antibody W3 blocked the formation of these 
tubular structures. D) Tumour cells survive by evading apoptosis. However, use of siRNAs directed 
towards LRP/LR successfully induced apoptosis in certain cancer types via LRP down-regulation 
(Adapted from [136]). 
 
 
 
 
Anti-LRP/LR specific 
antibody 
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1.2.9 RNA interference 
RNA interference refers to a conserved, specific mechanism of gene silencing used by a vast 
majority of eukaryotes
[160]
. This silencing functions to either suppress transcription (a process 
referred to as transcriptional gene silencing/ [TGS]) or activate a process of degradation of 
RNA (a sequence-specific process that is referred to as RNA interference/ [RNAi] or post-
transcriptional gene silencing/ [PTGS])
[160]
. This regulatory silencing mechanism is employed 
by siRNAs, which are double-stranded RNA (dsRNA) molecules that facilitate the 
degradation of sequences that are present in and complimentary to the target mRNA
[161]
. The 
key players in the [PTGS]/[RNAi] process are dsRNA molecules that serve to activate and 
induce this process due to their involvement in inducer-molecule cleavage and degrading of 
target mRNA
[161]
. 
Two enzyme complexes, namely Dicer and RNA-induced signalling complex (RISC), have 
been identified to play pivotal roles in the [PTGS]/[RNAi] processes
[161]
 (Figure 16). 
Specifically, Dicer facilitates initiation of this process
[162]
, whilst RISC is responsible for 
degradation of the target mRNA
[163]
.  
 1.2.9.1 Dicer 
Dicer is an enzyme complex that is highly specific for dsRNA and forms part of the RNase 
III nuclease family
[164]
. Structurally, Dicer is composed of four domains: a dsRNA-binding 
domain, dual RNase III motifs, a PAZ domain, and an amino-terminal helicase domain
[164]
. 
Functionally, Dicer acts by binding to long dsRNA molecules and cleaving them in order to 
yield short nucleotide duplexes (approximately 21-23 bp in length) consisting of 2-
overhanged nucleotides present at the 3’ ends[165]. These duplexes are known as small 
interfering ribonucleic acids (siRNAs)
[165]
. Further dsRNA digestion by RNase III nucleases 
yields fragments of about 12-15 bp in length, and this occurs as a result of the action of two 
centres of catalysis found within the dimeric RNase III enzyme
[165]
. Moreover, it is stipulated 
that four catalytic sites are formed as a consequence of Dicer folding onto the dsRNA 
substrate – thereby facilitating dsRNA digestion to form siRNA[166]. Essentially, it is 
suggested that two catalytic sites remain active and share maximum homology with the 
catalytic sequence of RNase III
[166]
. The other two sites experience loss-of-function due to the 
sharing of only partial homology
[166]
. Resultantly, Dicer-processed dsRNA exhibit a doubling 
in size in comparison to fragments processed by alternative RNase III nuclease enzymes
[166]
.  
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 1.2.9.2 RNA-induced silencing complex (RISC) 
According to a study conducted on Drosophila cells, it was established that dsRNA 
molecules assist with the sequence-specific targeting of exogenous RNA transcripts
[162]
. 
Moreover, this study identified RNA as an essential component of the nuclease activity that 
leads to degradation of the target mRNA
[162]
. This nuclease activity that results in mRNA 
degradation is called the RNA-induced silencing complex or RISC
[162]
. Domain proteins that 
contribute to the formation of RISC include fragile X-related (FXR), Argonaute (Ago) and 
Tudor-Stapylococcus (Tudor SN) proteins
[167]
.  
1.2.9.3 RNA interference mechanism 
Although not fully elucidated, a proposed mechanism exists for the [PTGS]/[RNAi] 
process
[167]
. The mechanism incorporates three essential steps: 
Step 1 (Initiation) entails the binding of Dicer to a dsRNA molecule, with subsequent 
cleavage of this dsRNA into fragments that are 21-25 nucleotides in length
[168]
. These 
fragments are termed siRNA
[168]
(Fig.16A).  
Step 2 (Effector)   involves the joining of siRNAs to the RISC
[169]
. siRNAs are organized into 
double-stranded, duplexed structures consisting of 3' two-nucleotide overhangs  and 5' 
phosphate termini
[167]
. This organization permits siRNAs to be incorporated into RISC
[167]
. 
ATP addition, as well as siRNA unwinding, are implicated in the enzymatic activation of 
RISC zymogens, with the outcome of only the most stable siRNA strand staying in 
attachment with RISC
[166]
 (Fig.16B).  
Step 3 (Gene silencing) is characterized by cleavage of target mRNA by the activated RISC 
multinuclease complex accompanied by the bound, stable siRNA strand
[168]
 (Fig.16C). It is 
understood that target mRNA is endonucleolytically cleaved at a point that is central to the 
complementary siRNA region, and this point is located ten nucleotides upstream from the 
paired nucleotide at the guide siRNA's 5' end
[169]
. Cleavage of target mRNA may occur 
independently of ATP, but the presence of ATP increases the efficiency at which cleaved 
products are released
[168]
.  
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Figure 16: The mechanism of RNA interference. A) Enzyme complex dicer binds to and cleaves dsRNA 
into siRNA fragments. B) RISC incorporates siRNA and binds to complementary sequences on target 
mRNA. C) After binding, the activated RISC facilitates cleavage and degradation of the target mRNA 
(http://eng.thesaurus.rusnano.com/upload/iblock/775/RNA-interference_1.jpg) 
. 
 1.2.9.4 RNA interference applications 
The use of RNA interference as a means of therapeutics has gained much attention with 
regards to the treatment of several gene-related ailments
[170]
 including genetic and 
autoimmune diseases, viral-based infections, and cancer – the latter being integral to the 
present study. Essentially, RNA interference may be applied to one gene or several genes to 
correct their disease-causing activity
[170]
. In vitro introduction of siRNAs and subsequent 
gene silencing is easily achievable, but due to off-target effects that may negatively impact 
healthy cells, siRNA-mediated gene silencing in vivo proves to be an ongoing challenge. 
Although challenging, several lines of research have permitted the development of RNA 
interference-based therapeutics to treat an array of viral infections, commonly HIV and 
hepatitis viruses
[171]
. Moreover, studies have provided insight into the use of RNAi-based 
therapeutics to treat neurodegenerative disorders and cancer
[172]
.  
  
  
A) 
B) 
C) 
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CHAPTER 2: RATIONALE, AIM AND OBJECTIVES 
2.1 Rationale and research question 
It has been observed that several types of tumour cells exhibit a characteristic over-
expression of the 37kDa/67kDa laminin receptor (LRP/LR) in comparison to their normal 
cell counterparts. This over-expression has been identified as a key factor in the enhancement 
of tumour progression. Importantly, LRP/LR has been implicated as a critical component in 
the maintenance of tumour cell viability – evidenced by reductions in cellular viability upon 
down-regulation of this receptor. Studies have proven that siRNA-mediated LRP/LR 
knockdown led to reductions in the viability of liver (Hep3B), lung (A549) and cervical 
(HeLa) cancer cells via apoptotic induction. Another study suggested that siRNA-mediated 
down-regulation of LRP/LR reduced the viability of breast (MCF-7 and MDA-MB231) and 
oesophageal (WHC01) cancer cells. These findings prompted the question whether siRNA-
mediated knockdown of LRP/LR will reduce the viability of pancreatic cancer (AsPC-1) and 
neuroblastoma (IMR-32) cells, and to establish whether apoptosis is the form of cell death 
responsible for the possible reduction in cellular viability. 
2.2 Aim 
To determine how siRNA-mediated down-regulation of the 37-kDa/67-kDa laminin receptor 
(LRP/LR) impacts on the cellular viability of pancreatic cancer (AsPC-1) and neuroblastoma 
(IMR-32) cells. 
2.3 Objectives 
 To assess cell surface LRP/LR levels on the afore-mentioned cell lines (Section 2.1) 
by employing flow cytometry 
 To successfully down-regulate the expression of LRP/LR in the cell lines mentioned 
above (Section 2.1) via cell transfection with siRNAs targeted to LRP mRNA.  
 To determine endogenous levels of LRP/LR in the above-mentioned cell lines 
(Section 2.1) and also to detect siRNA-mediated LRP/LR down-regulation by use of 
Western blotting  
 To analyse the effect of siRNA-mediated LRP/LR down-regulation on the viability of 
the above-mentioned cell lines (Section 2.1) using MTT assays 
 To determine the effect of siRNA-mediated LRP/LR knockdown on the proliferation 
of the above-mentioned cell lines (Section 2.1) using BrdU assays 
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 To assess if any nuclear morphological changes occur upon siRNA treatment 
targeting LRP/LR in the afore-mentioned cell lines (Section 2.1) using 
immunofluorescence microscopy 
 To detect possible apoptosis-inducing effects of siRNA-mediated LRP/LR down-
regulation on the cell lines stated in Section 2.1 by use of Annexin-V-FITC assays as 
well as caspase-3 assays 
 To analyse specific pathways used by the afore-mentioned cell lines (Section 2.1) to 
undergo siRNA-assisted apoptotic induction by performing caspase-8 and caspase-9 
assays 
 To analyse data for statistical significance 
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CHAPTER 3: MATERIALS AND METHODS 
 
N.B. : A detailed list of suppliers/manufacturers of antibodies, reagents and equipment used 
to carry out the following experiments is given in APPENDIX A. 
 
3.1 Cell culture 
3.1.1 Cell lines 
 AsPC-1 (ATCC® CRL-1862): Human pancreatic adenocarcinoma – isolated from 
ascites of a 62-year old Caucasian female diagnosed with pancreatic cancer and 
initiated in nude mouse xenografts. 
 IMR-32 (ATTC® CCL-127): Human neuroblastoma – derived from an abdominal 
mass of a 13-month old Caucasian male. 
3.1.2 Cell culture media 
3.1.2.1 Specific requirements per cell line 
 AsPC-1: RPMI 1640 supplemented with 2mM L-glutamine, 10mM HEPES and 
sodium pyruvate 
 IMR-32: Eagle Minimum Essential Medium (EMEM) supplemented with 2mM L-
glutamine and 1% non-essential amino acids 
For complete growth media, the above-mentioned media was additionally supplemented 
with: 
 10% Fetal calf serum (FCS) which is heat inactivated 
 1% Penicillin-Streptomycin 
3.1.3 Method of cell cultivation  
Both cell lines were cultivated in their respective media as described in section 3.1.2.1 above. 
The cells were grown in a humidified 5% CO2 incubator set at a temperature of 37°C in order 
to mimic in vivo conditions. Cells were seeded and sub-cultured at appropriate dilution 
factors and densities as often as was necessary. Seeding and sub-culturing of cells involved 
aspiration of the media followed by washing of the cells with 1-2ml of phosphate buffered 
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saline (PBS) to remove excess media. Thereafter, cells were detached using trypsin/EDTA 
and re-suspended in fresh media specific to the cell type as stated in section 3.1.2.1.  
3.1.4 Cryopreservation and storage of cells 
Both of the mammalian cell lines employed in this study were cryopreserved to alleviate cell 
loss occurring as a result of contamination or reaching too high a passage number. 
Cryopreservation also allowed for cell storage over long periods of time or until needed.    
The process of cryopreservation involved cell detachment by use of trypsin/EDTA post 
washing of the cells with PBS. Thereafter, detached cells were resuspended in their growth 
media and centrifuged at 1200 rpm for 10 minutes before discarding of the supernatant and 
re-suspension of the cell pellet in fresh warmed cell culture medium. Additional 
supplementation of the medium with 10% FCS and 10% DMSO served as the freezing 
medium. Following re-suspension, cells in 1ml aliquots were incubated for 1 hour at a 
temperature of -20°C prior to being incubated at -70°C overnight. Ultimately, cells were 
transferred to and stored in liquid nitrogen until required.   
3.1.5 Thawing of cells 
In the event that a cryopreserved stock of cells was needed, 1ml of fresh cell culture medium 
pre-warmed at 37°C was used to thaw the 1ml frozen cell stock and the resulting suspension 
was centrifuged at 1200 rpm for 10 minutes. After discarding the supernatant, the cell pellet 
was re-suspended in fresh media containing an additional 10% FCS and left to attach and 
grow at 37°C as previously described. 
3.1.6 Cell counting 
Cell counting was performed in order to ensure that a constant number of cells was used for 
experiments performed on both cell lines, thereby allowing for effective comparison between 
the cell lines involved in this study. Essentially, cell counting involved staining of cells with 
Trypan blue – in principle, viable cells appear clear whilst dead cells are stained blue. Post-
staining, cells were then counted using a Neubauer haemocytometer. After washing of the 
cells with PBS and detaching them with trypsin/EDTA, cells were re-suspended in the 
appropriate media and an aliquot of this cell suspension was combined with an equal amount 
of Trypan- blue solution (0.4%). Thereafter, 10µl of this combination was placed on the 
haemocytometer and the mean cell average in 16 small squares was counted under the light 
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microscope. The following formula was employed in order to determine the total number of 
cells (for each of a total of four quadrants): 
Number of cells/ml= Average count of unstained cells per 16 squares x 10
4
 x dilution factor 
  
3.2 siRNA-mediated down-regulation of the laminin receptor (LRP/LR) 
3.2.1 Materials 
 24-well, 6-well, and 6cm plates 
 siRNA-LAMR1 (targeted to LRP/LR) 
 siRNA-scrambled (employed as a negative control) 
 DharmaFect1 Transfection reagent 
 Serum-free media (containing no FCS) 
 Antibiotic-free media (containing no penicillin-streptomycin) 
 esiRNA-RPSA (targeted to LRP/LR)* 
 esiRNA-RLUC (employed as a negative control)* 
 Lipofectamine transfection reagent* 
*N.B.: These treatments were used following the same procedure described in section 
3.2.2 below, but were used only in SDS-PAGE/Western blotting (sections 3.3 and 3.4) 
and MTT assays (section 3.6) as a means of confirmation of the results obtained using 
siRNA-LAMR1 and siRNA-scrambled. 
3.2.2 Transfection procedure 
Prior to transfection, cells were seeded on appropriate plates at specific densities dependent 
on the experiment or assay to be performed. Cells were allowed to reach an approximate 
confluency of 50-70% before transfection was carried out. The target siRNA as well as the 
negative control siRNA were both diluted in specified amounts of serum-free media (as per 
manufacturers recommendations – Refer to Appendix A), followed by further dilution in 
suggested volumes of antibiotic-free media prior to being added to the cells. It is noteworthy 
that cells were also supplemented with recommended amounts of transfection reagent in 
order to facilitate the transfection procedure. Thereafter, the plates were incubated at 37°C for 
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a period of 72 hours to allow for transfection to occur prior to downstream experiments being 
performed. 
 
3.3 Protein biochemistry 
3.3.1 Preparation of cell lysates 
3.3.1.1 Materials 
 Cell scrapers 
 Phosphate buffered saline (1X PBS) 
 Lysis buffer [composed of: 10mM Tris/HCl pH 7.5, 10mM EDTA, 100mM NaCl, 
0.05% (w/v) deoxycholic acid (DOC), 0.5% (v/v) Nonidet-P40] 
3.3.1.2 Methodology 
Attached cells were washed with PBS prior to incubation in 500µl of lysis buffer for 2 
minutes. Thereafter, cell scrapers were used to facilitate cell detachment and membrane 
disruption. The resultant solution was placed in an Eppendorf tube and incubated at 4°C for 
15 minutes. This was followed by centrifugation of the tube at 14000 rpm for 2 minutes, after 
which the supernatant containing the extracted proteins was retained and the pellet discarded. 
The supernatant was stored at -20°C and thawed at 4°C whenever required. 
3.3.2 BCA
TM 
assay for protein quantification 
      3.3.2.1 Principle underlying BCA
TM
 assays 
BCA
TM
 assays are used for the determination of the total protein concentration in the cells. 
This particular assay exploits the reduction of Cu
2+
 to Cu
+
 by peptide bonds found in 
proteins. Cu
+
, as well as a violet solution of bicinchoninic acid (BCA, 2,2’-Bichinolin-4,4’-
dicarbonicacid) is produced. Hence, measurement of absorbance at 562nm is proportional to 
the amount of protein in the sample, thus allowing for protein concentration to be determined. 
3.3.2.2 Materials 
 96-well plates 
 Eppendorf tubes 
 BCA assay kit 
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 ELISA reader 
3.3.2.3 Methodology 
Bovine serum albumin (BSA) standards of concentrations 0, 0.2, 0.4, 0.6, 0.8 and 1mg/ml 
were prepared and subsequently, 25μl of each standard was loaded into separate wells of a 
96-well plate in triplicate. Similarly, 25μl of cell lysates obtained from section 3.3.1 and 
diluted (1:5) was added to the 96-well plate in duplicate. Thereafter, 200μl of BCA reagents 
(copper II sulphate and bicinchoninic acid) combined in a ratio of 1:50 was added to the wells 
containing the BSA standards as well as the lysates. The plate was then incubated for 30 min 
at room temperature and thereafter, the absorbance of the resultant solutions was measured at 
a wavelength of 562nm by use of an ELISA reader. Construction of a standard curve allowed 
for extrapolation of the concentration of proteins. 
3.3.3 Sodium dodecyl sulphate - Polyacrylamide gel electrophoresis (SDS-PAGE) 
3.3.3.1 Materials 
 Stacking Tris buffer [0.5M Tris, pH 6.8] 
 Separating Tris buffer [3M Tris, pH 8.8] 
 10% ammonium persulfate (APS) in distilled water 
 TEMED 
 Protein molecular weight marker (pre-stained) 
 2X loading buffer [100mM Tris/HCl pH 6.8, 4% SDS, 2% β-mercaptoethanol, 20% 
glycerol, 0.02% bromophenol blue] 
 1X SDS running buffer [1% of 10X running buffer] 
 10X SDS running buffer [250mM Tris, 192mM glycine in distilled water, 10% SDS] 
 Gel casting apparatus 
3.3.3.2 Methodology 
In order to separate proteins in a lysate sample, SDS-PAGE was employed. This technique 
was performed before the detection of total and down-regulated LRP/LR levels by use of 
Western blotting. SDS-PAGE exploits the molecular weight of proteins as the main criterion 
for separation. Heating of the lysate samples in the presence of SDS allowed for proteins to 
be denatured and additionally, lysate samples were subjected to β-mercaptoethanol to 
facilitate protein denaturation through the reduction of disulphide bridges within proteins. 
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Apart from denaturation of proteins, SDS also imparts a uniform negative charge on proteins 
thereby allowing molecular weight to be the principal determinant in the separation process. 
The negatively charged proteins migrate to the anode of the electrical field and separation of 
the proteins is subsequently achieved on the basis of molecular size using a polyacrylamide 
gel with a specific pore size. The pore size is dependent on the amount of acrylamide used, 
whereby larger amounts of acrylamide allows for smaller pore sizes to be achieved and 
smaller amounts of acrylamide will result in larger pore sizes. In line with the present study, a 
12% polyacrylamide gel was used (Refer to Appendix A for gel composition). 
Post heating of the lysate samples at 95°C for 5 min in loading buffer to allow for protein 
denaturation, 10μg of samples were loaded onto the gel. The gel was resolved at 200 V for 
approximately 30-45 min. 
 
3.4 Western blotting and immunodetection of proteins 
3.4.1 Materials 
 Transfer buffer [20% methanol in 192mM glycine and 25mM Tris] 
 Blocking buffer [3% BSA in 1X PBS-Tween] 
 Wash buffer [0.1% Tween in 1X PBS] 
 Polyvinyldifluoride (PVDF) membrane  
 Whatman filter papers 
 100% methanol 
 Primary antibody (anti-LRP/LR specific antibody IgG1-iS18) solution (Refer to: 
Zuber et al, J.Gen.Virol., 2008) 
 Secondary antibody (anti-human IgG-HRP conjugated antibody) solution 
 Conjugated primary antibody (mouse monoclonal anti-β-actin peroxidase) for 
detection of loading control 
 Chemiluminescent substrate  
 Blotting device 
3.4.2 Experimental procedure 
Endogenous LRP/LR levels as well as siRNA-treated LRP/LR levels were determined by 
employing Western blotting that makes use of a primary and secondary antibody (Section 
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3.4.1). This technique entails the transfer of the proteins separated during SDS-PAGE 
(Section 3.3.3) onto a PVDF membrane followed by exposure to the afore-mentioned 
antibodies. The chemiluminescent substrate was used in order to detect the horseradish 
peroxidase (HRP) that is conjugated to the secondary antibody. Thereafter, the fluorescent 
light emission was captured onto an x-ray film and this step was performed in a dark room. 
Prior to exposure of the PVDF membrane to relevant antibodies, electro-blotting was 
performed. Soaking of Whatman filter papers in transfer buffer was carried out for 5 min 
whilst PVDF membranes (cut to the dimensions of the SDS-PAGE gel) were soaked firstly in 
ethanol for 2 min and for 5 min in transfer buffer thereafter. PVDF membranes were then 
placed between soaked Whatman papers that were assembled onto the electro-blotting device 
and the gels were placed on top of the membranes. Electro-blotting took place for 45 min at 
300V and 350A. Thereafter, the membranes were blocked for 1 hour using blocking buffer 
followed by a 1 hour incubation of the membranes in the primary antibody diluted in 
blocking buffer. Three washes in washing buffer (10 min each) were performed before 
incubation of the membranes in secondary antibody diluted in blocking buffer for 1 hour. 
Three washes were again performed as previously mentioned before the development of 
chemiluminescent detected proteins onto x-ray film. It is noteworthy that the afore-mentioned 
β-actin antibody, which was used to detect β-actin and thus serves as a loading control, is 
directly conjugated to HRP and therefore does not require a secondary antibody. 
Densitometry was performed to quantify protein levels and this was done using ImageJ
™
 
software. 
 
3.5 Flow cytometry (FACS analysis) 
3.5.1 Materials 
 Confluent cells 
 Trypsin/EDTA 
 4% paraformaldehyde 
 Primary antibody (anti-LRP/LR specific antibody IgG1-iS18) 
 Secondary antibody (anti-human phycoerythrin (PE)- coupled) 
 Anti-chloramphenicol acetyltransferase antibody (anti-CAT) produced in rabbit – to 
be used as a negative control primary antibody 
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 Allophycocyanin (APC) – produced in goat and directed towards rabbit IgG – to be 
used as a negative control secondary antibody 
 PBS 
3.5.2 Methodology 
Determination of the cell surface levels of laminin receptor (LRP/LR) was achieved through 
the use of fluorescence activated cell scanning (FACS analysis). This technique employs the 
principle of immunodetection whereby primary antibodies that are recognised by specific 
fluorochrome-coupled secondary antibodies are used for the detection of a target protein. The 
flow cytometer is comprised of an argon laser beam that facilitates differentiation between 
antibody-labelled cells and unlabelled cells, thus allowing for the expression of target 
proteins on the cell surface to be quantified.  
One of the essential requirements of flow cytometry is that cells need to be in suspension, 
hence trypsin/EDTA was used in order to assist with cell detachment. Thereafter, detached 
cells were centrifuged for 10 min at 1200 rpm followed by the resultant pellet being fixed 
with 4% paraformaldehyde for 10 min at 4°C. Post fixation, two cell suspensions were 
prepared by re-suspension of cell pellets in PBS and the halved – one half of the cell 
suspension was treated with primary antibody IgG1-iS18 (30 μg/ml) in PBS whilst the other 
half of the cell suspension was treated with only PBS (thus serving as a control). Following 
an overnight incubation at 4°C, cells were washed three times in PBS by centrifugation at 
5000 rpm for 5 min and both cell pellets were re-suspended in PBS and the PE-coupled 
secondary antibody. After incubation of both cell suspensions for 1 hour in the dark, the 
resulting cell suspensions were washed 3 times in PBS as previously described and re-
suspended in PBS before flow cytometric evaluation. The same procedure was followed in 
order to obtain results for the negative control bacterial protein, chloramphenicol 
acetyltransferase (CAT), using the negative control antibodies outlined in section 3.5.1 
above. Additionally, unlabelled cells were also used as a control.  
 
3.6 Assessment of cellular viability 
3.6.1 MTT assay 
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3.6.1.1 Principle behind the assay 
This assay is a colorimetric assay that relies on the ability of viable cells to cleave the 
mitochondrial tetrazolium salt (MTT), which is water-soluble and yellow in colour. Cleavage 
of MTT occurs via the mitochondrial succinate dehydrogenase (reductase) enzyme to 
produce water-insoluble purple formazan crystals (Fig.17). Therefore, by measurement of the 
absorbance of the resulting purple formazan crystal solution, a percentage of cell survival can 
be determined – with lower absorbance values corresponding to an enhanced level of cell 
death due to lower levels of MTT cleavage. 
 
Figure 17: The MTT assay reaction. Yellow MTT salt is cleaved by the action of mitochondrial 
succinate dehydrogenase to form purple formazan crystals (https://upload.wikimedia.org/ 
wikipedia/commons/d/de/MTT_reaction.png.) 
3.6.1.2 Materials 
 24-well plates 
 PBS 
 MTT (1mg/ml) 
 Dimethyl sulfoxide (DMSO) 
 ELISA plate reader 
 
3.6.1.3 Experimental procedure 
Both AsPC-1 and IMR-32 cells were grown to reach a density of approximately 1 x 10
5
 
cells/ml and 100µl of cells at this density were seeded per well prior to siRNA transfection. 
Post transfection, cells were incubated for 72 hours at 37°C. Thereafter, 100µg of MTT 
dissolved in PBS was added to each well, followed by a 2 hour incubation period at 37°C. 
Post incubation, the MTT-containing medium was discarded from each well and the 
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remaining formazan crystals were dissolved in 500µl of DMSO. The absorbance of the 
resulting formazan solution was measured at 570nm using an ELISA plate reader. It is 
important to note that controls included untreated cells, negative control siRNA treated cells, 
and positive control protocatechuic acid (PCA) treated cells. 
 
3.7 Analysis of cellular proliferation  
3.7.1 Bromodeoxyuridine (BrdU) assay 
      3.7.1.1 Principle of the assay 
This assay is a colorimetric immunoassay that quantifies bromodeoxyuridine (BrdU) that 
becomes incorporated into newly-formed DNA molecules of cells that are proliferating, as an 
indication of the proliferative state of cells. During the synthesis of nucleic acids, BrdU – 
which is an analogue of thymidine, becomes incorporated in place of thymidine (Fig.18). Use 
of a monoclonal detector antibody directed towards BrdU (anti-BrdU) and a horseradish 
peroxidase-conjugated antibody (directed towards the detector antibody) allows for the 
amount of actively proliferating cells to be determined. Essentially, horseradish peroxidase 
catalyzes the conversion of tetra-methylbenzidine (TMB), a chromogenic substrate, from a 
colourless solution to a blue solution – which can be quantified by measuring the absorbance 
using an ELISA plate reader.   
                                          
Figure 18: Principle of the bromodeoxyuridine (BrdU) assay.  BrdU is an analogue that becomes 
incorporated into newly-formed DNA of actively proliferating cells in place of thymidine. Use of an 
antibody directed to BrdU facilitates detection and quantification of cell proliferation (Adapted from: 
https://www.abdserotec.com/brdu-bromodeoxyuridine.html).                                                                                
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3.7.1.2 Materials 
 24-well plate 
 BrdU label 
 Fixative/denaturing solution 
 100X anti-BrdU antibody 
 BrdU antibody diluent 
 Peroxidase goat anti-mouse IgG 
 BrdU conjugate diluents 
 TMB chromogenic substrate solution 
 20X plate wash concentrate 
 Stop solution 
 PBS 
 Cell culture media 
 De-ionized water 
3.7.1.3 Experimental procedure 
Post seeding and transfection of cells at a density of 1 x 10
5
 cells/ml and 100µl of cells/well, 
80μl of a working stock of BrdU (dilution of BrdU label in fresh culture medium (1:2000)) 
was added to each well followed by a 2-24 hour incubation period at 37°C. Following 
aspiration of contents, 800μl of fixative solution was loaded to each well and incubated for 
30min at room temperature. After removal of the fixative by gentle blotting onto a paper 
towel, cells were subjected to an hour incubation in 100μl of anti-BrdU antibody (diluted to 
1X by use of the antibody diluent). Prior to a 30min incubation of cells (at room temperature) 
with 400µl of the peroxidase anti-mouse IgG HRP-conjugate antibody (reconstituted in 1X 
PBS and further diluted 1:1000 with conjugate diluent), wells were washed thrice with wash 
buffer (diluted to 1X using deionized water). Thereafter, 400μl of substrate solution was 
loaded followed by a subsequent incubation period of 15min, after three washes with wash 
buffer. Finally, absorbance was measured within 30min of addition of stop solution (400μl) at 
dual wavelengths of 450-540 nm. It is noteworthy that in addition to untreated cells being 
used as a control, siRNA-scr and PCA were used as negative and positive controls, 
respectively. 
 
42 
 
3.8 Assessment of nuclear morphological changes 
3.8.1 Confocal microscopy 
3.8.1.1 Materials 
 4% paraformaldehyde 
 PBS 
 Hoescht 33342 
 Slides  
 Coverslips 
 Mounting fluid 
3.8.1.2 Methodology 
This technique was employed in order to assess the nuclear morphological changes that occur 
after down-regulation of LRP/LR via the use of siRNA technology. 
Firstly, cells were grown at an approximate density of 1x10
5 
cells/ml and 100µl of cells at 
this density were seeded onto coverslips prior to siRNA transfection. Thereafter, cells were 
fixed in 4% paraformaldehyde for 15 minutes followed by three washes with PBS. Excess 
PBS was blotted off between each PBS wash and post washing, cells were treated with 
Hoescht 33342 nuclear stain diluted in PBS (1:100) for 5 to 10 minutes in the dark. The 
coverslips containing the Hoescht-treated cells were then washed 2-3 times in PBS and 
thereafter, coverslips were mounted (cell side down) onto a clean microscope slide using 
mounting fluid. After setting for 45 minutes in the dark, slides were stored at 4ºC until ready 
to view using a confocal microscope. Importantly, controls included untreated cells, cells 
treated with siRNA-scr (negative control) and PCA (positive control). 
 
3.9 Assessment of apoptotic induction 
3.9.1 Annexin V-FITC/ 7-AAD assay 
      3.9.1.1 Principle of the assay 
This assay is dependent on the ability of the calcium-dependent Annexin V protein to 
preferentially bind to the phosphatidylserine (PS) protein. Normally found to be located on 
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the intracellular membrane, PS translocates from the intracellular membrane to the outer 
surface during apoptosis and subsequent changes in the cellular surface (Fig.19). 
Translocation of PS to the outer surface enables Annexin V to bind to the protein in the 
presence of calcium, hence Annexin V staining allows for measurement of translocated PS 
and therefore allows for detection of apoptosis by means of flow cytometry. Additionally,  7-
amino-actinomycin D (7-AAD), which is a red-fluorescent dye that binds specifically to 
guanine-cytosine DNA base pairs, is employed in this assay (Fig.19) - allow for distinction 
between early apoptotic and late apoptotic or necrotic cells. Thus, viable cells will show no 
fluorescence, whilst apoptotic cells will fluoresce green and dead cells green as well as red. 
 
Figure 19: Principle of the Annexin V-FITC/ 7-AAD assay. Cells undergoing apoptosis experience a 
membrane-flip reaction that exposes phosphatidylserine (PS) on the outer cell membrane. Annexin V 
conjugated to FITC binds to this exposed PS, and FITC allows for detection of apoptotic cells. 7-AAD is a 
viability dye that is used to distinguish between early and late apoptotic cells 
(http://www.lifesci.dundee.ac.uk/sites/default/files/annexin.jpg). 
3.9.1.2 Materials 
 PBS 
 Trypsin/EDTA 
 Annexin V-FITC solution 
 1X Annexin-binding buffer  
 7-AAD viability dye 
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 Flow cytometer 
3.9.1.3 Experimental procedure 
Post seeding of cells to a density of 5 x 10
6 
cells/ml and subsequent siRNA transfection, cells 
were washed with ice-cold PBS after harvesting with trypsin/EDTA and thereafter, cell 
suspensions were centrifuged at 500 x g for 5 minutes. This was followed by discarding of 
the supernatant and re-suspension of the cell pellet in 1X annexin-binding buffer. 
Subsequently, 10µl of Annexin V-FITC solution and 20µl of 7-AAD viability dye was added 
to 100µl of the cell suspensions. The cell suspensions were then incubated on ice for 15 
minutes in the dark. Finally, samples were supplemented with 400μl of ice-cold 1X annexin 
binding buffer prior to flow cytometric analysis which was performed within 30 minutes. It 
must be noted that untreated cells, siRNA-scr treated cells, and PCA treat cells were used as 
controls, as with previously-described methods. The FL1 laser was used to detect Annexin V- 
FITC staining and FL3 was used for detection of 7-AAD staining. Compensation and 
quadrants were set using the following controls: unstained cells, Annexin V-FITC stained 
cells, 7-AAD stained cells, cells stained with both Annexin V-FITC and 7-AAD, and PCA-
treated cells stained with both Annexin V-FITC and 7-AAD.  
3.9.2 Caspase-3, -8 and -9 assays 
      3.9.2.1 Principle of the assays 
Caspase-3, -8 and -9 assays are colorimetric assays that rely on caspase-mediated hydrolysis 
of a chromophore known as p-nitroaniline (p-NA) that is coupled to a peptide substrate. In 
the case of caspase-3 assays, the peptide substrate is Asp-Glu-Val-Asp p-nitroaniline 
(DEVD-p-NA). Caspase-8 and -9 assays make use of substrates known as Ile-Glu-Thr-Asp p-
nitroaniline (IETD-p-NA) and Leu-Glu-His-Asp p-nitroaniline (LEHD-p-NA), respectively. 
In essence, each caspase recognizes a specific peptide sequence and subsequently cleaves that 
peptide, thereby releasing the p-NA chromophore – which possesses a high absorbance at 
405nm. Therefore, the concentration of p-NA released can be used as a directly-proportional 
indicator of caspase activity and consequently the occurrence of apoptosis. 
3.9.2.2 Materials 
 Cell lysis buffer* 
 2X reaction buffer* 
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 p-NA-coupled peptide substrate (4mM)* 
 DTT (1mM) 
 Eppendorf tubes 
 96-well plates 
*N.B.: Each of these components differ depending on the type of caspase assay being 
performed  
3.9.2.3 Experimental procedure 
Cells were grown to reach a density of 1x10
6 
cells/ml and after siRNA transfection, 1x10
6
 
cells were pelleted by centrifugation at 1200 rpm for 10 minutes. Thereafter, cells were re-
suspended in 50µl of cell lysis buffer and incubated on ice for 10 minutes. This was followed 
by centrifugation of cells at 10000 x g for 1 minute. The supernatant was then transferred to a 
fresh Eppendorf tube which was immediately placed on ice and the pellet was discarded. 
Following this, the protein concentration of the supernatant was determined by use of a 
BCA
TM
 assay (as described in section 3.3.2) and subsequently, 200µg of protein was diluted 
to 50µl of cell lysis buffer per sample and added to appropriate wells of a 96-well plate. The 
2X reaction buffer was then supplemented with DTT (10µl DTT/1ml reaction buffer) and 
50µl of this solution was added to each sample, followed by the addition of 5µl of peptide 
substrate. After a 2 hour incubation period at 37ºC, the plate was read at 405nm using an 
ELISA plate reader. In addition to untreated cells, siRNA-scr treated and PCA treated cells 
were used as negative and positive controls, respectively. 
 
3.10 Statistical evaluation 
The two-tailed Student’s t-test with a confidence interval of 95% was used in order to analyse 
the data, with p-values of less than 0.05 being considered as significant. This statistical 
analysis was done using Graphpad Prism version 5.03. Pearson’s correlation coefficient was 
also used to measure the correlation between LRP/LR levels and cell viability, cell 
proliferation and apoptotic induction. A positive coefficient was an indication of direct 
proportionality between the two variables, whereas a negative coefficient implied inverse 
proportionality. Values close to or rounding off to 1 signifies high positive correlation.  
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CHAPTER 4: RESULTS 
4.1 High percentages of pancreatic cancer and neuroblastoma cells exhibit LRP/LR on 
their cell surface. 
It is understood that LRP/LR plays a pivotal role in the maintenance of cellular viability. 
Therefore, in light of the present study, it was necessary to confirm the presence of LRP/LR 
on the cell surface and to quantify the percentage of cells displaying cell surface LRP/LR 
within a specific cell population. This was achieved by use of flow cytometry. Figure 20 
depicts that both of the tumourigenic cell lines exhibited high percentages of cells within a 
given cell population that display LRP/LR on their cell surface. The distinct shift between the 
peaks is characteristic of changes in fluorescence intensity occurring as a result of treatment 
of cells with anti-LRP/LR specific antibody IgG1-iS18 and a relevant secondary antibody 
that is conjugated to a fluorochrome. It was observed that 93.48% of pancreatic cancer 
(AsPC-1) cells and 84.90% neuroblastoma (IMR-32) cells displayed LRP/LR on the cell 
surface, thus confirming the presence of the protein on the surface of both of the cell lines in 
question.  
 
                   
 
Figure 20: Detection of the 37kDa/67kDa laminin receptor LRP/LR levels on the surface of 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. The green peak is representative of 
cells that have not been labelled with antibodies, whilst the blue peak represents cells that have been 
stained only with goat anti-human phycoerythin (PE)-coupled secondary antibody. The red peak is 
indicative of cells that have been stained with both anti-LRP/LR specific antibody IgG1-iS18 and the 
afore-mentioned secondary antibody. It is noteworthy that the inclusion of an unlabelled control confirms 
that the secondary antibody does not bind non-specifically, hence no shift in fluorescence intensity is 
observed between the green and blue peaks. The shifts observed between the green and red peaks indicate 
the presence of LRP/LR on the cell surface of both the tumourigenic cell lines under study. The above 
plots represent an average of experiments that were carried out in triplicate and repeated at least three 
times, with 20 000 cells being counted per sample and samples being analysed using filter 2 (FL-2) which 
is specific for the PE fluorochrome.  
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Similarly, anti-CAT specific antibody targeted to chloramphenicol acetyltransferase (CAT) 
was used as a negative control due to the absence of CAT on the surface of mammalian cells. 
As expected, both cell lines showed no shift in fluorescence intensity, thus indicating that 
CAT was indeed absent on the cell surface of the tumourigenic cell lines and therefore served 
as an effective negative control (Fig.21). 
 
                              
 
Figure 21: Determination of chloramphenicol acetyltransferase levels on the surface of pancreatic 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells. The black peak is indicative of cells that are 
unlabelled, whilst the orange peak is representative of cells that have been stained with goat anti-rabbit 
allophycocyanin (APC)-coupled secondary antibody only. The pink peak represents cells that have been 
labelled with both anti-CAT primary antibody and the afore-mentioned secondary antibody which is 
specific for the primary antibody. No distinct shift was seen between the black and orange peaks, thus 
indicating that the secondary antibody did not bind non-specifically. Moreover, no shift was observed 
between the unlabelled peak and the peak representing cells stained with both primary and secondary 
antibodies – thereby indicating the absence of the CAT protein on the surface of both the tumourigenic cell 
lines in question. It is noteworthy that the above plots are representative of an average of experiments that 
were carried out in triplicate and repeated at least three times, with 20 000 cells being counted per sample. 
Samples were analysed using filter 4 (FL-4) which is specific for detection of the APC fluorochrome. 
 
4.2 Neuroblastoma cells exhibit higher cell surface LRP/LR levels in comparison to 
pancreatic cancer cells. 
In addition to determining the percentage of cells within a given population that exhibit cell 
surface LRP/LR, the actual levels of cell surface LRP/LR within that cell population was also 
analysed using flow cytometry. In essence, the same concentration of the primary antibody 
IgG1-iS18 and PE-coupled secondary antibody was used to label the same number of cells 
(20 000) within a specific population of both cell lines over the same period of time. It 
therefore follows that the more LRP/LR present on the surface of these cancer cells, the 
C
el
l 
co
u
n
t 
Fluorescence intensity (FL-4) 
AsPC-1 IMR-32 
Unlabelled 
APC only 
Anti-CAT and  
APC 
48 
 
higher the level of binding of the IgG1-iS18 primary antibody and subsequently the IgG-
specific PE-coupled secondary antibody will be. Therefore, the median fluorescence intensity 
(MFI) can be used as an indicator of differential cell surface LRP/LR expression (Table 1). It 
was observed that neuroblastoma (IMR-32) cells display significantly higher cell surface 
LRP/LR levels (70% more) in comparison to pancreatic cancer (AsPC-1) cells, as depicted in 
figure 22. 
Table 1: Median fluorescence intensity (MFI) values used to determine differential expression of 
LRP/LR on the surface of AsPC-1 and IMR-32 cells.   
Cell line MFI of unlabelled 
cells (A) 
MFI of cells stained 
with IgG1-iS18 and 
PE-coupled 
secondary antibody 
(B)  
Difference in MFI 
values i.e. (B) – (A) 
AsPC-1 6857.19 10768.00 3910.83 
IMR-32 996.17 13690.33 12694.17 
*All MFI values are representative of an average of experiments carried out in triplicate and 
repeated at least three times. 
 
 
Figure 22: Quantification of LRP/LR levels on the surface of pancreatic cancer (AsPC-1) and 
neuroblastoma (IMR-32) cells by flow cytometry. For both tumourigenic cell lines, cells were labelled 
with primary antibody IgG1-iS18 and anti-human phycoerythrin (PE)-coupled secondary antibody. 
Analysis was performed on 20 000 cells per sample and the median fluorescence intensity (MFI) was used 
as an indicator of differential cell surface LRP/LR expression across both cell lines. It is noteworthy that 
the MFI values presented in the last column of table 1 was used in the construction of this graph and the 
MFI value representative of the IMR-32 cell line was set to 100%. IMR-32 cells were found to have 70% 
more cell surface LRP/LR than AsPC-1 cells. Experiments were carried out in triplicate and repeated at 
least three times. ***p<0.0001 
0
20
40
60
80
100
120
M
ed
ia
n
 f
lu
o
re
sc
e
n
ce
 i
n
te
n
si
ty
 (
%
) 
Cell lines 
 IMR-32    AsPC-1 
***  
49 
 
A similar analysis was performed using the median fluorescence intensity values obtained for 
the CAT negative control protein (Table 2). As previously described, 20 000 cells within a 
specific population of each cell line was labelled with the same concentration of primary anti-
CAT antibody and goat anti-rabbit allophycocyanin (APC)-coupled secondary antibody and 
incubated over the same time period. Thus, MFI values could be used as an indicator of 
differential surface expression of CAT protein levels across both the tumourigenic cell lines. 
As was expected, no significant difference was observed in cell surface CAT expression 
between AsPC-1 and IMR-32 cells (Fig.23). 
Table 2: Median fluorescence intensity (MFI) values used as an indicator of differential expression 
of chloramphenicol acetyltransferase (CAT) on the surface of AsPC-1 and IMR-32 cells. 
Cell line MFI of unlabelled 
cells (A) 
MFI of cells stained 
with anti-CAT 
primary and APC-
coupled secondary 
antibody (B)  
Difference in MFI 
values i.e. (B) – (A) 
AsPC-1 427.33 819.00 391.67 
IMR-32 99.33 446.33 347.00 
*All MFI values are representative of an average of experiments carried out in triplicate and 
repeated at least three times. 
 
Figure 23: Quantification of cell surface chloramphenicol acetyltransferase (CAT) levels on 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells by flow cytometry. Both cell lines 
were labelled with anti-CAT primary antibody and allophycocyanin (APC)-coupled secondary antibody. 
Median fluorescence intensity (MFI) values were used to assess differential expression of CAT on the cell 
surface of both cell lines and 20 000 cells were analysed per sample. MFI values given in the last column 
of table 2 were used to construct this graph and the value corresponding to AsPC-1 cells was set to 100%. 
Experiments were performed in triplicate and repeated at least three times. N.S.:p= 
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4.3 Neuroblastoma cells display significantly higher total LRP/LR levels in comparison to 
pancreatic cancer cells. 
As previously stated, LRP/LR is not solely expressed on the cellular surface and is 
additionally found in the cytosol, nucleus and the perinuclear region. Therefore, Western 
blotting was carried out in order to determine total LRP/LR levels across both of the 
tumourigenic cell lines under study. Experiments were performed in triplicate and repeated 
three times, and a representative blot (Fig.24A) is given for both LRP/LR and β-actin – with 
the latter being used as a loading control. It is important to note that anti-LRP/LR specific 
antibody IgG1-iS18 was only successful in detection of the 37kDa laminin receptor precursor 
(LRP) form. The Western blots revealed that both the pancreatic cancer (AsPC-1) and the 
neuroblastoma (IMR-32) cells express LRP. However, densitometric quantification suggested 
that IMR-32 cells display 63% more total LRP when compared to AsPC-1 cells (Fig.24B). 
 
 
 
 
Figure 24: Assessment of relative expression of total 37kDa laminin receptor precursor (LRP) levels 
on pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. A) Anti-LRP/LR specific primary 
antibody IgG1-iS18 and a HRP-coupled secondary antibody specific for the primary antibody was used to 
detect total 37kDa LRP levels in both of these tumourigenic cell lines. β-actin was used as a loading 
control. B) Densitometric analysis performed on these blots revealed that IMR-32 cells possess 63% more 
total LRP in comparison to AsPC-1 cells. It is noteworthy that the data is representative of an average of 
experiments performed in triplicate and repeated three times. Values obtained from quantification of LRP 
were divided by values obtained from β-actin quantification, and the resultant values were used in the 
construction of this graph. The resultant value for IMR-32 cells was set to 100%. ***p=0.0003 
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4.4 Use of siRNA technology leads to successful down-regulation of LRP expression in 
pancreatic cancer and neuroblastoma cells. 
In order to gain insight into the effect of LRP/LR expression on cellular viability, siRNA-
mediated knockdown of LRP/LR was performed. Post transfection of pancreatic cancer 
(AsPC-1) and neuroblastoma (IMR-32) cells with siRNA-LAMR1 (specifically targeting the 
mRNA of the 37kDa LRP), Western blot analysis and subsequent densitometry was 
performed as previously described. Densitometric analysis revealed that LRP was 
successfully down-regulated in both AsPC-1 (Fig.25A and 25B) and IMR-32 (Fig.26A and 
26B) cells by transfection with the afore-mentioned siRNA. It was observed that siRNA-
LAMR1 transfected AsPC-1 and IMR-32 cells exhibited a 90% and 71% reduction in LRP 
expression, respectively, when compared to non-transfected cells whose LRP/LR levels were 
set to 100%. Moreover, transfection of AsPC-1 cells with siRNA-scr (negative control 
scrambled siRNA) showed no significant LRP knockdown when compared to non-transfected 
cells (Fig.25C and 25D). Likewise, the same effect was observed when IMR-32 cells were 
transfected with siRNA-scr (Fig.26C and 26D).  
 
                              
                              
                                                     
Figure 25: LRP expression in pancreatic cancer (AsPC-1) cells after siRNA transfection. A and B) 
Transfection of AsPC-1 cells with siRNA-LAMR1 resulted in significant LRP knockdown of 90% when 
compared to non-transfected cells. Densitometry values obtained for LRP were divided by those for the β-
actin loading control and resultant values were used to construct this graph. The value for the non-
transfected cells was set to 100%. C and D) Densitometry revealed no significant difference in LRP 
expression between non-transfected and siRNA-scr control transfected cells. **p=0.0086, N.S.:p=0.1665. 
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Figure 26: Detection of LRP expression in neuroblastoma (IMR-32) cells post siRNA transfection. A 
and B) Densitometry revealed that there was a significant reduction of 71% in LRP expression after 
transfection of IMR-32 cells with siRNA-LAMR1 when compared to non-transfected cells. Densitometry 
values obtained for LRP were divided by values for the β-actin loading control. Resultant values were used 
in the construction of this graph and the value for non-transfected cells was set to 100%. C and D) No 
significant difference in LRP expression was observed between non-transfected and siRNA-scr transfected 
cells. Graphs depict values that are an average of experiments done in triplicate and repeated three times. 
*p=0.0117, N.S.: p=0.1148 hence non-significant. 
 
4.5 siRNA-mediated down-regulation of LRP expression results in significantly reduced 
viability of pancreatic cancer and neuroblastoma cells. 
After siRNA-mediated knockdown of LRP was observed, the effect thereof on cellular 
viability was analysed. Following treatment of AsPC-1 and IMR-32 cells with siRNA-
LAMR1, MTT assays revealed that cellular viability was significantly reduced in comparison 
to controls. This signifies that siRNA-mediated LRP knockdown leads to the observed 
decreases in cellular viability in both of the tumourigenic cell lines. It was seen that AsPC-1 
and IMR-32 cells treated with siRNA-LAMR1 exhibited 82% and 75% reductions in cellular 
viability, respectively, when compared to non-transfected cells whose cell viability readings 
were set to 100% (Fig.27). Moreover, no significant reduction in cellular viability was 
observed for both cell lines when treated with the negative control siRNA-scr and compared 
to non-transfected cells (Fig.27). Protocatechuic acid (PCA) was used as a positive control 
treatment as it is a known apoptosis inducer which acts by impacting the activity of cell-cycle 
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   regulatory proteins and inflammatory cytokines – thereby hampering oncogenic cell growth[173]. 
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Figure 27: The effect of siRNA-mediated LRP knockdown on the viability of pancreatic cancer 
(AsPC-1) and neuroblastoma (IMR-32) cells. MTT assays were used to analyse the viability of AsPC-1 
and IMR-32 cells after treatment with siRNA-LAMR1. The value for non-transfected cells was set to 
100% for both cell lines and by comparison, AsPC-1 and IMR-32 cells treated with siRNA-LAMR1 
displayed a significant reduction of 82% and 65% in cellular viability, respectively. Cells treated with the 
negative control siRNA-scr showed no significant differences in cellular viability when compared to non-
transfected cells for both cell lines. Protocatechuic acid (PCA) was used as a positive control. Graph is 
representative of an average of experiments performed in triplicate and repeated three times. **p=0.0017, 
***p=0.0008, N.S.: p>0.05 hence non-significant. 
 
4.6 Use of an alternative siRNA confirms that LRP down-regulation is responsible for 
reductions in cellular viability in pancreatic cancer and neuroblastoma cells. 
In order to ascertain whether the observed reduction in cellular viability occurred as a result 
of siRNA-LAMR1-mediated LRP down-regulation and not an off-target effect, another 
siRNA that targets a different region of LRP was used. Post transfection of cells with this 
alternative siRNA (esiRNA-RPSA), Western blot analysis and densitometry was performed. 
By comparison to non-transfected cells (which was set to 100%), pancreatic cancer (AsPC-1) 
cells showed a significant knockdown of 83% in LRP expression (Fig.28A and 28B). 
Similarly, neuroblastoma (IMR-32) cells exhibited a significant down-regulation of 64% in 
LRP expression when compared to non-transfected cells (Fig.29A and 29B). Additionally, 
treatment of AsPC-1 cells with esiRNA-RLUC (negative control siRNA) displayed no 
significant difference in LRP expression when compared to non-transfected cells (Fig.28C 
and 28D). Likewise, the same effect was observed for IMR-32 cells treated with esiRNA-
RLUC (Fig.29C and 29D).  
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Figure 28: Detection of LRP expression in pancreatic cancer (AsPC-1) cells post transfection with an 
alternative siRNA. A and B) After transfection of cells with esiRNA-RPSA, densitometry showed that 
there was a significant reduction of 83% in LRP expression when compared to non-transfected cells, which 
was set to 100% as previously described. β-actin was used as a loading control. C and D) Densitometry 
revealed that there was no significant difference in LRP expression between cells treated with the negative 
control siRNA (esiRNA-RLUC) and non-transfected cells. Graphs are representative of an average of 
experiments performed in triplicate and repeated three times. **p=0.0057, N.S.:p=0.6613 hence non-
significant. 
 
                                   
                                   
                                                    
Figure 29: LRP expression in neuroblastoma (IMR-32) cells after transfection with an alternative 
siRNA. A and B) Densitometry revealed that after treatment of IMR-32 cells with esiRNA-RPSA, there 
was a significant reduction of 64% in LRP expression when compared to non-transfected cells. Non-
transfected cells were set to 100% to allow for comparison and β-actin was used as a loading control. C 
and D) Densitometric quantification showed no significant difference in LRP expression between non-
transfected cells and cells treated with esiRNA-RLUC (negative control siRNA). Graphs are indicative of 
an average of experiments carried out in triplicate and repeated three times. *p=0.0250, N.S.:  
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To assess the effects of esiRNA-RPSA-mediated LRP knockdown on the viability of AsPC-1 
and IMR-32 cells, MTT assays were performed. It was found that treatment of cells with this 
alternative siRNA resulted in significantly reduced cellular viability in both the tumourigenic 
cell lines under study. Specifically, AsPC-1 cells showed an 82% reduction in cellular 
viability post siRNA treatment whilst IMR-32 cells exhibited a 60% reduction when 
compared to non-transfected cells – which were set to 100% (Fig.30). Moreover, treatment of 
both cell lines with the negative control siRNA (esiRNA-RLUC) did not result in a 
significant change in cellular viability when compared to non-transfected cells (Fig.30). Only 
Western blotting and MTT assays were repeated using the alternative siRNA and control 
siRNA. The same trend is seen with both siRNA-LAMR1 and esiRNA-RPSA with regards to 
cell viability studies, confirming that it is the specific targeting and knock-down of LRP/LR 
that reduces the cell viability in the tumourigenic cells being investigated.   
 
  
Figure 30: The effect of an esiRNA-RPSA-mediated LRP down-regulation on the viability of 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. Post treatment of cells with this 
alternative siRNA, MTT assays were performed to assess cellular viability. Compared to non-transfected 
cells (set to 100%), AsPC-1 and IMR-32 cells showed reductions of 82% and 60% in cellular viability, 
respectively, after being treated with esiRNA-RPSA. No significant differences were observed in the 
viability of cells treated with the negative control siRNA (esiRNA-RLUC) when compared to non-
transfected cells for both cell lines. PCA was used as a positive control and the graph is representative of 
an average of experiments performed in triplicate and repeated three times. **p=0.0014, ***p=0.0005, 
N.S.: p>0.05 therefore non-significant. 
All of the results that follow are representative of experiments performed using only siRNA-
LAMR1 and siRNA-scr. 
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4.7 Knockdown of LRP expression by siRNA significantly reduces proliferation of 
pancreatic cancer and neuroblastoma cells. 
Due to the observed reduction in cellular viability of pancreatic cancer (AsPC-1) and 
neuroblastoma (IMR-32) cells upon treatment with siRNA, the effect of siRNA-mediated 
down-regulation of LRP expression on cellular proliferation was also investigated – since a 
loss in cellular viability could be a result of reduced proliferation rates. Cellular proliferation 
was analysed by use of BrdU assays.  
It was observed that AsPC-1 and IMR-32 cells showed significant reductions of 76% and 
44% in cellular proliferation, respectively, after being treated with siRNA-LAMR1 and 
compared to non-transfected cells which were set to 100% (Fig.31). Furthermore, treatment 
of both cell lines with the negative control siRNA (siRNA-scr) showed no significant 
differences in cellular proliferation when compared to non-transfected cells (Fig.31).  
 
Figure 31: The effect of siRNA-mediated LRP knockdown on the proliferation of pancreatic cancer 
(AsPC-1) and neuroblastoma (IMR-32) cells. Post treatment of cells with siRNA-LAMR1, AsPC-1 cells 
showed a 76% reduction in cellular proliferation when compared to non-transfected cells (set to 100%). 
IMR-32 cells showed a decrease of 44% in proliferation after siRNA-LAMR1 treatment by comparison to 
non-transfected cells. Treatment of both cell lines with the negative control siRNA-scr revealed no 
significant changes in cellular proliferation when compared to non-transfected cells. Protocatechuic acid 
was used as a positive control and the graph is representative of an average of experiments carried out in 
triplicate and repeated three times. **p=0.0053 and 0.0031 for AsPC-1 and IMR32 cells, respectively. 
N.S.: p>0.05 thus non-significant. 
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4.8 siRNA-mediated knockdown of LRP expression results in nuclear morphological 
changes suggestive of apoptotic induction in pancreatic cancer and neuroblastoma cells. 
To examine if apoptotic induction led to the reductions in cellular viability post siRNA-
LAMR1 treatment, possible nuclear morphological changes were detected by confocal 
microscopy. Compared to the nuclei of non-transfected cells (Fig.32A), siRNA-LAMR1 
treated pancreatic cancer (AsPC-1) cells displayed nuclear morphological changes such as the 
formation of apoptotic bodies (Fig.32D). Similarly, comparison of nuclei of siRNA-LAMR1 
treated neuroblastoma (IMR-32) cells (Fig.33D) to the nuclei of non-transfected cells 
(Fig.33A) revealed nuclear morphological changes such as nuclear shrinkage, membrane 
blebbing and the formation of apoptotic bodies. Moreover, treatment of both cell lines with 
the negative control siRNA-scr did not result in nuclear morphological changes when 
compared to non-transfected cells (Fig.32B and 33B). PCA was used as a positive control for 
studying nuclear morphological changes under apoptotic conditions (Fig.32C and 33C). 
      
       
Figure 32: The effect of siRNA-mediated LRP knockdown on nuclear morphology of pancreatic 
cancer (AsPC-1) cells. A) Non-transfected cells showed normal rounded nuclei with uncompromised 
integrity. B) Cells treated with the negative control siRNA-scr displayed nuclei similar to that of the non-
transfected cells. C) PCA treated cells showed nuclei that have undergone membrane blebbing and 
apoptotic body formation (indicated by white arrows). D) siRNA-LAMR1 transfected cells exhibited 
diminished nuclear integrity and the formation of apoptotic bodies (shown by white arrows), suggesting 
apoptotic induction. All images were obtained at a magnification of 63X. Scale bar applies to all images. 
A) B) 
C) D) 
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Figure 33: Changes in nuclear morphology in neuroblastoma (IMR-32) cells after siRNA-mediated 
LRP down-regulation. A) Nuclear integrity is maintained in non-transfected cells, evident by the normal 
rounded shape of nuclei. B) Negative control siRNA-scr transfected cells showed no interruptions in 
nuclear morphology, as expected. C) Positive control PCA treated cells showed nuclear shrinkage 
(indicated by white arrows). D) siRNA-LAMR1 transfected cells showed compromised nuclear integrity, 
made clear by the observation of nuclear shrinkage and apoptotic body formation (shown by white 
arrows). All images were obtained at 63X magnification and the scale bar applies to all images.  
 
4.9 siRNA-mediated down-regulation of LRP expression leads to apoptotic induction in 
pancreatic cancer and neuroblastoma cells. 
Confocal microscopy suggested that knockdown of LRP expression in pancreatic cancer 
(AsPC-1) and neuroblastoma (IMR-32) cells causes nuclear morphological changes that are 
characteristic of cells undergoing apoptotic induction. In order to confirm that this 
observation of apoptotic induction holds true for both of the tumourigenic cell lines in 
question, Annexin V-FITC/ 7-AAD assays were performed. 
It was observed that transfection of AsPC-1 cells with siRNA-LAMR1 resulted in 76% of 
cells undergoing apoptotic induction (Fig.34D) when compared to non-transfected cells 
(Fig34A). Treatment of IMR-32 cells with siRNA-LAMR1 led to 42.7% of cells 
experiencing apoptotic induction (Fig.35D) in comparison to non-transfected cells (Fig.35A). 
Furthermore, treatment of both cell lines with the negative control siRNA-scr did not result in 
A) B) 
C) D) 
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apoptotic induction (Fig.34B and 35B). Protocatechuic acid (PCA) was used as a positive 
control and led to high percentages of both cell lines that underwent apoptotic induction 
(Fig.34C and 35C).  
     
                                                                            
Figure 34: Apoptotic induction in pancreatic cancer (AsPC-1) cells after siRNA transfection. A) 
Non-transfected cells show that majority of cells lie in the lower left quadrant (Q1-LL) and this quadrant is 
indicative of normal living cells. B) Treatment of cells with the negative control siRNA-scr also resulted in 
majority of the cells appearing in the lower left quadrant. C) Protocatechuic acid (PCA) was used as a 
positive control and resulted in most of the cells appearing in the upper right quadrant (Q1-UR), which is 
representative of cells undergoing late apoptosis. D) Transfection of cells with siRNA-LAMR1 led to 0.8% 
of cells undergoing early apoptosis, as shown in the lower right quadrant (Q1-LR), and 75.2% of cells 
undergoing late apoptosis – therefore a total of 76% of cells underwent apoptosis after siRNA-LAMR1 
treatment. The upper left quadrant (Q1-UL) is indicative of cells undergoing necrosis. 20 000 cells were 
counted per sample and plots are representative of an average of experiments done in triplicate and 
repeated three times. 
 
 
       
 
Figure 35: Induction of apoptosis in neuroblastoma (IMR-32) cells post siRNA transfection. A) 
Majority of non-transfected cells appeared in the lower left quadrant, indicative of living cells. B) siRNA-
scr transfected cells were mostly also found in the lower left quadrant. C) PCA treated cells mostly 
appeared in the upper right quadrant, indicative of cells undergoing late apoptosis. D) 7.5% of cells 
transfected with siRNA-LAMR1 were found to be undergoing early apoptosis (lower right quadrant), 
whilst 35.2% of siRNA-LAMR1 transfected cells were observed as undergoing late apoptosis (upper right 
quadrant) – thus a total of 42.7% of siRNA-LAMR1 treated cells underwent apoptosis. 20 000 cells were 
counted per sample and plots are indicative of an average of experiments performed in triplicate and 
repeated three times. 
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4.10 The level of apoptotic induction after siRNA-mediated LRP knockdown is 
significantly higher in pancreatic cancer cells than neuroblastoma cells. 
In order to quantify the levels of apoptotic induction occurring after treatment of pancreatic 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells with siRNA-LAMR1, the combined 
percentage values obtained for early and late apoptosis for each cell line (Fig.34D and 35D) 
were used as an indication of total apoptosis levels. It was observed that AsPC-1 cells 
underwent 44% more total apoptosis than IMR-32 cells after siRNA-LAMR1 transfection 
(Fig.36).  
 
Figure 36: Total levels of apoptotic induction in pancreatic cancer (AsPC1) and neuroblastoma 
(IMR-32) cells after siRNA-mediated LRP knockdown. After transfection of cells with siRNA-
LAMR1, it was observed that AsPC-1 cells underwent 44% more apoptosis than IMR-32 cells. Total 
apoptosis values post siRNA-LAMR1 transfection were obtained from the annexin V-FITC/ 7-AAD 
assays and the total apoptosis values obtained for the corresponding non-transfected cells were subtracted. 
Resultant values were used in the construction of this graph and AsPC-1 cells were set to 100%. Graph 
represents an average of experiments performed in triplicate and repeated three times. ***p<0.0001 
 
4.11 siRNA-mediated knockdown of LRP expression leads to significantly increased 
caspase-3 activity in pancreatic cancer and neuroblastoma cells. 
To further confirm that down-regulation of LRP as a result of treatment of cells with siRNA-
LAMR1 leads to apoptotic induction in pancreatic cancer (AsPC-1) and neuroblastoma 
(IMR-32) cells, caspase-3 activity assays were performed. It was found that after transfection 
with siRNA-LAMR1, AsPC-1 cells displayed a significant 10-fold increase in caspase-3 
activity when compared to non-transfected cells which were set to 100% (Fig.37). IMR-32 
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cells showed a 6-fold increase in caspase-3 activity after treatment of cells with siRNA-
LAMR1 and compared to non-transfected cells (Fig.37). Additionally, treatment of both cell 
lines with the negative control siRNA-scr showed no significant differences in caspase-3 
activity when compared to non-transfected cells (Fig.37). 
 
Figure 37: The effect of siRNA-mediated LRP down-regulation on caspase-3 activity in pancreatic 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells. Caspase-3 activity assays showed that after 
treatment of cells with siRNA-LAMR1, AsPC-1 and IMR-32 cells showed a significant 10-fold and 6-fold 
increase in caspase-3 activity, respectively, when compared to non-transfected cells (which was set to 
100%). No significant difference was observed when both cell lines were treated with the negative control 
siRNA-scr and compared to non-transfected cells. Prototechuic acid (PCA) was used as a positive control. 
Graph is indicative of an average of experiments performed in triplicate and repeated three times. 
*p=0.0109 and 0.0154 for AsPC-1 and IMR-32, respectively. N.S: p>0.05 hence non-significant. 
 
4.12 Pancreatic cancer and neuroblastoma cells exhibit significantly increased caspase-8 
activity after siRNA-mediated down-regulation of LRP expression. 
To further ascertain that siRNA-mediated LRP knockdown induces apoptosis in pancreatic 
cancer (AsPC-1) and neuroblastoma (IMR-32) cells, caspase-8 activity assays were 
performed. Additionally, this assay was used to gain insight into whether or not the caspase-
8-mediated extrinsic pathway is used by each of the two cell lines to induce apoptosis post 
transfection with siRNA-LAMR1. It was observed that AsPC-1 and IMR-32 cells treated 
with siRNA-LAMR1 experienced a significant 3-fold and 4-fold increase in caspase-8 
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activity, respectively, when compared to non-transfected cells which were set to 100% 
(Fig.38). Moreover, transfection of both cell lines with the negative control siRNA-scr 
revealed no significant differences in caspase-8 activity when compared to non-transfected 
cells (Fig.38).  
 
Figure 38: The effect of siRNA-mediated knockdown of LRP expression on caspase-8 activity in 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. siRNA-LAMR1 transfected AsPC-1 
and IMR-32 cells showed a significant 3-fold and 4-fold increase in caspase-8 activity, respectively, when 
compared to non-transfected cells (set to 100%). Treatment of both cell lines with the negative control 
siRNA-scr resulted in no significant difference in caspase-8 activity when compared to non-transfected 
cells. PCA was used as a positive control. The graph is representative of an average of experiments carried 
out in triplicate and repeated three times. *p=0.0357, **p=0.0053, N.S: p>0.05 thus non-significant. 
 
4.13 Pancreatic cancer cells show a significant increase in caspase-9 activity after siRNA-
mediated LRP knockdown. 
Caspase-9 activity assays were used in order to establish whether or not pancreatic cancer 
(AsPC-1) and neuroblastoma (IMR-32) cells use the caspase-9-mediated intrinsic pathway to 
induce apoptosis after siRNA-mediated LRP knockdown. It was found that AsPC-1 cells 
exhibit a significant 3-fold increase in caspase-9 activity after transfection of cells with 
siRNA-LAMR1, when compared to non-transfected cells which were set to 100% (Fig.39). 
No significant difference was observed in caspase-9 activity in IMR-32 cells treated with 
siRNA-LAMR1 by comparison to non-transfected cells (Fig.39). Furthermore, treatment of 
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both cell lines with the negative control siRNA-scr resulted in no significant differences in 
caspase-9 activity when compared to non-transfected cells, as expected (Fig.39).  
 
Figure 39: The effect of siRNA-mediated down-regulation of LRP expression on caspase-9 activity in 
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. siRNA-LAMR1 transfected AsPC-1 
cells showed a significant 3-fold increase in caspase-9 activity when compared to non-transfected cells (set 
to 100%). Treatment of IMR-32 cells with siRNA-LAMR1 showed no difference in caspase-9 activity by 
comparison to non-transfected cells. Both tumourigenic cell lines displayed no significant difference in 
caspase-9 activity after treatment of cells with the negative control siRNA-scr, and by comparison to non-
transfected cells. PCA was used as a positive control. Graph represents an average of experiments carried 
out in triplicate and repeated three times. **p=0.0016, N.S.: p>0.05 thus non-significant.   
 
4.14 Pearson’s correlation co-efficient  
Table 3: Pearson’s correlation co-efficients (R) between cell surface and total LRP levels prior to 
siRNA transfection. 
Cell lines Correlation between cell surface and total 
LRP levels prior to siRNA transfection (R-
value) 
AsPC-1 0.72 
IMR-32 0.97 
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Table 4: Pearson’s correlation co-efficients (R) between total LRP levels prior to and post siRNA-
LAMR1 transfection. 
Cell lines Correlation between total LRP levels prior 
to and post siRNA-LAMR1 transfection 
(R-value) 
AsPC-1 0.90 
IMR-32 0.92 
 
Table 5: Pearson’s correlation co-efficients (R) between total LRP levels prior to and post 
transfection with esiRNA-RPSA. 
 
Table 6: Assessment of correlation between levels of siRNA-mediated LRP knockdown and 
reductions in the viability of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells, using 
Pearson's correlation co-efficients (R). 
Cell lines Correlation between 
siRNA-LAMR1-mediated 
LRP knockdown and 
reduction in cellular 
viability (R-value) 
Correlation between 
esiRNA-RPSA-mediated 
LRP knockdown and 
reduction in cellular 
viability (R-value) 
AsPC-1 0.99 0.92 
IMR-32 0.96 0.99 
 
   
 
 
 
Cell lines Correlation between total LRP levels prior 
to and post esiRNA-RPSA transfection (R-
value) 
AsPC-1 0.80 
IMR-32 0.94 
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Table 7: Correlation between siRNA-mediated LRP down-regulation and reductions in cellular 
proliferation and viability in AsPC-1 and IMR-32 cells by use of Pearson's correlation co-efficients 
(R). 
Cell lines Correlation between 
siRNA-LAMR1-mediated 
LRP knockdown and 
reduction in cellular 
proliferation (R-value) 
Correlation between 
siRNA-LAMR1-mediated  
reductions in both cellular 
proliferation and cellular 
viability (R-value) 
AsPC-1 0.99 0.99 
IMR-32 0.85 0.96 
 
Table 8: Pearson’s correlation co-efficients (R) between total LRP levels post siRNA-LAMR1 
transfection and total levels of apoptosis. 
 
Table 9: Pearson’s correlation co-efficients (R) between total LRP levels post siRNA-LAMR1 
transfection and increases in caspase-3 activity after siRNA-LAMR1 treatment. 
 
 
 
 
Cell lines Correlation between total LRP levels post 
siRNA-LAMR1 transfection and total 
levels of apoptosis (R-value) 
AsPC-1 0.92 
IMR-32 0.99 
Cell lines Correlation between total LRP levels post 
siRNA-LAMR1 transfection and increases 
in caspase-3 activity after siRNA-LAMR1 
treatment (R-value) 
AsPC-1 0.99 
IMR-32 0.91 
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CHAPTER 5: DISCUSSION 
Over time, the involvement of LRP/LR in tumourigenesis has largely gained the interest of 
the scientific community due to evidence that this receptor exhibits a characteristic over-
expression in several cancerous cell types in comparison to normal cells. Specifically, tumour 
progression is enhanced by the LRP/LR-assisted promotion of processes such as tumour 
angiogenesis, metastasis and apoptotic evasion. As previously stated, LRP/LR is not confined 
only to the cell surface but is additionally localized in the cytosol, nucleus and the perinuclear 
region. The vast localization of LRP/LR implicates it in many protein interactions, allowing 
the receptor to serve several physiological functions such as cell adhesion, cell migration and 
proliferation, cellular viability maintenance, regulation of cell cycle functioning, protein 
synthesis and ribosomal RNA processing. Due to LRP/LR over-expression, these functions 
may be exploited in tumour cells, leading to the occurrence of the afore-mentioned tumour-
promoting processes. Thus, this receptor may be considered as a promising target for cancer 
prognosis and therapeutics. 
5.1 Analysis of the difference in cell surface LRP/LR levels between pancreatic cancer and 
neuroblastoma cells 
Flow cytometry revealed significantly high percentages of both pancreatic cancer (AsPC-1) 
and neuroblastoma (IMR-32) cells displaying LRP/LR on the cell surface. However, these 
percentages are only indicative of the percentage of cells within a given population that 
display an unknown amount of cell surface LRP/LR. To further investigate and quantify the 
actual levels of LRP/LR expression on the cell surface, median fluorescence intensities were 
used and revealed that IMR-32 cells exhibited significantly higher (70% more) cell surface 
LRP/LR levels in comparison to AsPC-1 cells. This difference might be due to the possibility 
that neuroblastoma cells are more dependent on LRP/LR to carry out processes such as cell 
adhesion and invasion, however this assumption will require further investigation involving 
comparative studies of the invasive potential of IMR-32 and AsPC-1 cells and the 
involvement of LRP/LR therein. Additionally, it may be speculated that IMR-32 cells could 
be more reliant on LRP/LR to facilitate cellular proliferation and the maintenance of cellular 
viability – two essential functions served by LRP/LR as a transmembrane cell-surface 
receptor.  Another possible explanation as to why IMR-32 cells exhibit increased LRP/LR 
levels may be due to interactions of this receptor with the cellular prion protein (PrP). PrP is a 
ligand for LRP/LR
[174]
 and, although ubiquitously expressed, it has been found to be 
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expressed in higher quantities in neuronal cells
[175]
. Thus, it may be possible that increased 
LRP/LR expression observed in the neuroblastoma cell line under investigation is a means of 
compensation used by neuronal cells to allow for adequate binding of PrP molecules. 
Moreover, the bacterial protein chloramphenicol acetyltransferase (CAT) was used as an IgG 
isotypic negative control due to its expected absence in eukaryotic cells. CAT proved to be a 
highly efficient control, showing no significant differences in cell surface expression between 
the two tumourigenic cell lines and confirming that it is the specificity of IgG1-iS18 that 
results in LRP/LR recognition and not simply due to non-specific IgG binding. 
5.2 Assessment of the difference between total LRP levels in pancreatic cancer and 
neuroblastoma cells 
As previously described, LRP/LR is predominantly a cell-surface transmembrane receptor 
but is also found in other cellular locations. Therefore, even though differences were 
observed in cell-surface LRP/LR levels between AsPC-1 and IMR-32 cells, total LRP/LR 
levels (which incorporates LRP/LR found in the nucleus, cytosol, perinuclear region, and also 
on the cell surface) were also determined. Western blotting and densitometry revealed that 
IMR-32 cells contain 63% more total LRP compared to AsPC-1 cells. This increased total 
LRP level in IMR-32 cells may suggest that, in comparison to AsPC-1 cells, this cell line 
could be more dependent on LRP/LR to maintain nuclear structures and execute translational 
processes – in line with the functions served by LRP/LR in the nucleus and cytosol, 
respectively. Importantly, it must be noted that majority of the observed total LRP levels can 
be attributed to cell-surface LRP due to the high correlation observed between these two 
parameters. This is relevant due to cell-surface LRP being predominantly implicated in the 
maintenance of cellular viability. 
5.3 Silencing of LRP 
RNA interference was used to down-regulate LRP/LR in order to assess the role of this 
receptor in cellular viability. A specific siRNA called siRNA-LAMR1 was employed to 
facilitate this down-regulation. siRNA-LAMR1 targets the mRNA of the 37kDa laminin 
receptor precursor (LRP) form, particularly targeting the open reading frame region of the 
human LRP gene. Western blotting was employed to detect LRP knockdown using anti-
LRP/LR specific antibody IgG1-iS18, which only successfully detects the 37kDa LRP – 
possibly due to cytoplasmic extractions containing the 67kDa LR form in significantly low 
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concentrations. Treatment of AsPC-1 and IMR-32 cells with siRNA-LAMR1 revealed a 90% 
and a 71% reduction in LRP expression, respectively, when compared to non-transfected 
cells – thereby proving the efficacy of siRNA-LAMR1.  
Moreover, the fact that AsPC-1 cells showed a greater reduction in LRP expression after 
siRNA-LAMR1 supplementation in comparison to IMR-32 cells may possibly be attributed 
to IMR-32 cells having higher total LRP levels than AsPC-1 cells before siRNA treatment. 
Essentially, the same density of cells from both cell lines were treated with the same volume 
and concentration of siRNA-LAMR1 with regards to preparation of lysates. Hence, it can be 
suggested that this volume of siRNA-LAMR1 was more effective in targeting majority of the 
LRP in AsPC-1 cells due to the lower total LRP level in AsPC-1 cells prior to siRNA 
transfection. Similarly, it may be possible that the volume of siRNA-LAMR1 used was less 
effective in targeting LRP in IMR-32 cells due to the higher total LRP level before siRNA 
transfection. Furthermore, a high correlation was observed between total levels of LRP prior 
to and post siRNA-LAMR1 transfection, thus suggesting that higher levels of LRP 
expression prior to siRNA treatment leads to less LRP knockdown after siRNA treatment, 
and vice versa. 
As previously mentioned, siRNA-LAMR1 targets the 37kDa LRP and not the 67kDa LR 
form of the receptor. However, owing to the fact that LRP is a precursor of LR, reduced 
expression of LRP would consequently result in reduced maturation to the LR form. 
Moreover, the post-translation modification known as fatty acylation is responsible for the 
maturation of the 37kDa LRP into the 67kDa LR form and since this maturation does not 
occur through direct transcription or translation, the 67kDa LR is unable to be directly 
targeted. 
It is noteworthy that a negative control scrambled siRNA, called siRNA-scr, was used to 
control for the effects of siRNA-LAMR1. The control siRNA was designed to not target any 
known gene within the cell and is necessary to distinguish between silencing that is sequence-
specific and non-specific effects. Additionally, this control siRNA has been designed to exert 
minimal or no effect on cellular viability and phenotype. It is evident that siRNA-scr did not 
significantly affect LRP expression in both AsPC-1and IMR-32 cells.  
Even though siRNA-LAMR1 is specific for LRP in relation to the control siRNA-scr, which 
had no effect on LRP expression, it cannot be disregarded that the effects of siRNA-LAMR1 
on cell viability might have been due to off-target effects and not specifically the down-
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regulation of LRP/LR. Therefore, another siRNA called esiRNA-RPSA which is specific for 
LRP was used. This siRNA also specifically targets the mRNA of the 37kDa LRP, similarly 
to siRNA-LAMR1. However, BLAST analysis revealed that siRNA-LAMR1 targets the 
37kDa LRP mRNA at nucleotides 250-268, whilst esiRNA-RPSA targets nucleotides 521-
929 of the mRNA sequence. Treatment of AsPC-1 and IMR-32 cells with esiRNA-RPSA 
yielded significant reductions of 83% and 64%, respectively, in LRP expression. This result 
is similar to that of the outcome observed when using siRNA-LAMR. Furthermore, a high 
correlation was observed between total LRP levels prior to and post esiRNA-RPSA 
treatment. This reiterates the suggestion that higher levels of total LRP before siRNA 
treatment results in less LRP knockdown post siRNA treatment. 
Due to the fact that both of the afore-mentioned LRP-specific siRNAs target completely 
different regions of the LRP mRNA but yield similar effects, it can be said that the results 
observed upon using siRNA-LAMR1 are a direct outcome of down-regulation of LRP 
specifically. Furthermore, esiRNA-RLUC served as the negative control siRNA that controls 
for the action of esiRNA-RPSA. This control siRNA targets Renilla Luciferase (RLUC), 
which is absent in the cell lines under study. No significant difference was observed in LRP 
expression when AsPC-1and IMR-32 cells were treated with this negative control siRNA, 
thus proposing high specificity of esiRNA-RPSA for LRP. 
5.4 Association between LRP expression and cellular viability maintenance 
In order to gain insight into the role played by LRP/LR in the maintenance of cellular 
viability, siRNAs were used to down-regulate LRP expression and the effect thereof on the 
cellular viability of AsPC-1 and IMR-32 cells was assessed using MTT assays. Treatment of 
AsPC-1 and IMR-32 cells with siRNA-LAMR1 resulted in an 82% and 65% reduction in 
cellular viability, respectively, when compared to non-transfected cells. This observation 
reveals a crucial role for LRP/LR in the maintenance of cellular viability, as the knockdown 
of this receptor results in significantly lowered cell viability. Moreover, high correlation was 
observed between the extent of siRNA-LAMR1-mediated LRP knockdown in AsPC-1 and 
IMR-32 cells, and the siRNA-LAMR1-induced reduction in cellular viability in these two 
cell lines. This further justifies that LRP/LR is essential to the maintenance of cellular 
viability. Similarly, transfection of AsPC-1 and IMR-32 cells with esiRNA-RPSA resulted in 
reductions of 82% and 60% in cellular viability, respectively, when compared to non-
transfected cells. This observation is in line with that of cells treated with siRNA-LAMR1, 
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hence providing further evidence of the critical role of LRP/LR in cellular viability 
maintenance. Furthermore, high correlation exists between esiRNA-RPSA-mediated LRP 
down-regulation in AsPC-1 and IMR-32 cells and reductions in cellular viability induced by 
esiRNA-RPSA treatment. 
Additionally, treatment of AsPC-1 and IMR-32 cells with siRNA-scr and esiRNA-RLUC - 
the negative control siRNAs for siRNA-LAMR1 and esiRNA-RPSA, respectively - showed 
no effect on cellular viability, thus proving their high efficacy as negative controls and 
affirming the specificity of their respective target-siRNA counterparts. Treatment of cells 
with 8mM protocatechuic acid (PCA) - an apoptotic inducer employed as a positive control in 
this study - showed reductions in cellular viability paralleled to that of cells treated with 
siRNA-LAMR1 and esiRNA-RPSA, as expected.   
It is clear that LRP/LR plays an important role in the maintenance of cellular viability, and 
moreover, tumour cells characteristically evade apoptosis to facilitate tumour progression. As 
previously stated, a proposed mechanism by which LRP/LR maintains cellular viability is 
through interactions with a growth factor known as Midkine. This growth factor exhibits high 
affinity for binding to heparin and is critically involved in the retention of the stability of 
chromosomes that affords LRP/LR the ability to maintain cellular viability
[127]
. Essentially, 
Midkine has been associated with cellular processes such as angiogenesis, cellular 
proliferation and migration
[127]
. Furthermore, several cancer types have displayed up-
regulated Midkine expression in comparison to their normal cell counterparts. Recent studies 
have revealed an over-expression of Midkine in neuroblastoma
[176]
 and pancreatic
[177]
 tumour 
cells - the two cell types central to the present study. It is suggested that this over-expression 
results in the up-regulation of cell survival promoting factors (such as Bad and PKB) and 
assists in apoptotic inhibition via caspase-3 suppression
[178]
. Ultimately, siRNA-mediated 
LRP knockdown may possibly result in subsequently reduced LRP/LR-Midkine interactions, 
thus causing the observed reductions in cellular viability. 
5.5 Involvement of LRP expression in cellular proliferation 
In order to establish whether impaired cellular division is responsible for the reductions in 
cellular viability of AsPC-1 and IMR-32 cells, cellular proliferation was analysed. BrdU 
assays revealed that after transfection of both these cell lines with siRNA-LAMR1, AsPC-1 
and IMR-32 cells experience reductions of 76% and 44% in cellular proliferation, 
respectively, in comparison to non-transfected cells. This suggests that LRP/LR plays a role 
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in cellular division that consequently facilitates cellular viability maintenance. Treatment of 
both cell lines with the negative control siRNA-scr showed no significant impact on cellular 
proliferation when compared to non-transfected cells. On the other hand, treatment of cells 
with the positive control PCA showed reductions in cellular proliferation that are similar to 
those observed for siRNA-LAMR1 treated cells.  
Furthermore, a high correlation was observed between total levels of siRNA-LAMR1-
mediated LRP knockdown in AsPC-1 and IMR-32 cells, and siRNA-LAMR1-induced 
reductions in cellular proliferation. This further confirms the crucial involvement of LRP/LR 
in cellular proliferation. Additionally, a high correlation was seen between siRNA-LAMR1-
mediated reductions in cellular viability and cellular proliferation, thus confirming that the 
processes of cellular proliferation and cellular viability maintenance are both affected by 
LRP/LR RNA interference.  
It is evident that LRP/LR is involved in the process of cellular proliferation and additionally, 
Midkine is a growth factor that also plays a role in this process - as previously highlighted. 
The use of siRNA-LAMR1 to knock down LRP resulted in decreased proliferation of AsPC-
1 and IMR-32 cells, and this may be attributed to decreased LRP expression being inadequate 
in interactions with Midkine. The reduction in the LRP/LR-Midkine interaction possibly 
impeded cellular proliferation and hence the maintenance of cellular viability was 
compromised. LRP/LR has also been identified in interactions with certain proteins that 
govern cell cycle progression, such as cyclins A2 and B1, CDK’s 1 and 2, and p21[123], thus 
knockdown of this receptor may result in hampered cellular growth and proliferation.   
5.6 Influence of LRP expression on apoptotic induction 
To identify whether apoptosis was the form of cell death responsible for the observed 
reduction in the viability of AsPC-1 and IMR-32 cells after LRP down-regulation, confocal 
microscopy was used. After treatment of these two cell lines with siRNA-LAMR1, evident 
alterations in nuclear morphology were observed – such as nuclear shrinkage, nuclear 
membrane blebbing, and the formation of apoptotic bodies – when compared to the nuclear 
morphology of non-transfected cells. Due to the maintenance of nuclear structures by the 
binding of nuclear and perinuclear LRP/LR to histones
[113]
, it is clear that knockdown of this 
receptor leads to diminished nuclear integrity and altered nuclear morphology. These siRNA-
LAMR1-induced changes to the nuclear morphology of AsPC-1 and IMR-32 are indicative of 
apoptotic induction in these cell lines. Moreover, apoptotic induction exhibits characteristic 
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disruptions in DNA structure
[99]
, thereby deeming Hoescht staining as an effective method of 
detection of apoptosis due to its capacity to bind to double stranded DNA. Additionally, 
treatment of both cell lines with the negative control siRNA-scr showed no disruptions in 
nuclear morphology, evidenced by the similarity to non-transfected cells. Positive control 
PCA-treated cells showed alterations in nuclear morphology that are suggestive of apoptotic 
induction, and this was expected due to PCA being an apoptotic inducer. 
Although confocal microscopy indicated the occurrence of apoptosis in AsPC-1 and IMR-32 
cells, further confirmation and quantification of apoptotic induction was required. This was 
achieved by use of Annexin-V-FITC/ 7-AAD assays. Essentially, apoptosis involves loss of 
integrity of cell membranes that results in a membrane-flip reaction which exposes 
intracellularly-located phosphatidylserine (PS) on the outer cell membrane – thereby 
permitting Annexin-V to bind to PS when calcium is present
[179]
. Importantly, the Annexin-V 
protein is conjugated to a fluorochrome known as FITC, which allows for the binding of 
Annexin-V to PS to be detected without impacting on the binding capacity of Annexin-V. 
However, it is impossible to differentiate between early and late apoptosis solely by Annexin-
V binding, thus a viability dye known as 7-AAD is additionally used to achieve this. 
Specifically, 7-AAD is only incorporated into late apoptotic cells which have experienced 
membrane alterations (allowing the dye to stain DNA within the nucleus), and is excluded 
from early apoptotic cells which lack this feature
[180]
.  
It was observed that non-transfected and negative control siRNA-scr transfected cells for 
AsPC-1 and IMR-32 cells exhibited negative staining for Annexin-V, therefore appearing in 
the lower left quadrant which is representative of living cells. On the other hand, 8mM PCA-
treated and siRNA-LAMR1-treated AsPC-1 and IMR-32 cells  displayed positive staining for 
Annexin-V – appearing in the lower right and upper right quadrants. The shift from negative 
to positive Annexin-V staining signifies that siRNA-LAMR1-mediated LRP down-regulation 
in AsPC-1 and IMR-32 cells triggers blebbing of the cell membrane, which is characteristic 
of cells undergoing apoptosis. This blebbing exposes PS on the outer cell membrane and 
allows Annexin-V to bind, as previously described. Both cell lines showed majority of cells 
experiencing late apoptosis after siRNA-LAMR1 transfection, specifically 75.2% of AsPC-1 
and 35.2% of IMR-32 cells. Further quantification suggested that AsPC-1 cells underwent 
44% more total apoptosis than IMR-32 cells, thus proposing that siRNA-LAMR1 is more 
successful in knocking down LRP in AsPC-1 cells than it is in IMR-32 cells and 
subsequently causing more cell membrane blebbing in AsPC-1 cells. This was further 
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justified by the high correlation observed between total levels of LRP after siRNA-LAMR1 
treatment and total levels of apoptosis for both cell lines.   
Although majority of AsPC-1 and IMR-32 cells underwent late apoptosis after transfection 
with siRNA-LAMR1, relatively high percentages of these cell types also experienced 
necrosis after this treatment. Necrotic cells appear in the upper left quadrant and it was 
observed that 22% of AsPC-1 cells and 27.7% of IMR-32 cells underwent necrosis post 
siRNA-LAMR1 transfection. One possible explanation for this observation may be that the 
72-hour transfection period was too long, thus causing necrotic cell death instead of late 
apoptosis. However, this speculation requires further time-dependent studies to assess 
whether the same effect is observed when the transfection period is shortened.  
Nuclear morphological studies as well as Annexin V assays proved that siRNA-mediated 
knockdown of LRP expression leads to apoptotic induction in AsPC- 1 and IMR-32 cells. 
Additionally, caspase-3 assays were performed in order to further ascertain the occurrence of 
apoptotic induction after treatment of these cell lines with siRNA-LAMR1. Caspase-3 is an 
effector caspase that exhibits increased activity in cells that are actively undergoing 
apoptosis
[181]
. After treatment of AsPC-1 and IMR-32 cells with siRNA-LAMR1, there was a 
marked increase in caspase-3 activity in both cell lines when compared to non-transfected 
cells. These findings clearly indicate that siRNA-mediated LRP down-regulation induces 
apoptosis in these two tumourigenic cell lines, possibly due to the reduction in or inhibition 
of the afore-mentioned LRP/LR-Midkine interaction. This observation of apoptotic induction 
after siRNA-mediated LRP knockdown may also be attributed to the interaction of LRP/LR 
with focal adhesion kinase (FAK). A recent study showed that after LRP/LR binds to 
laminin, interactions can occur between LRP/LR and FAK
[182]
. These interactions were 
implicated in the activation of PI3-kinase/AKT and MEK/ERK 1/2 cell survival pathways 
and also the up-regulation of Bcl-2 - an anti-apoptotic protein
[182]
. Thus, siRNA-mediated 
knockdown of LRP in the present study may perhaps be preventing the LRP/LR-FAK 
interaction and thereby inducing apoptosis. Alternatively, down-regulation of LRP by 
siRNAs in the present study may have led to apoptotic induction due to the ribosomal 
functions of LRP/LR. It is known that LRP/LR plays a role in the biogenesis of ribosomes by 
facilitating 21S pre-rRNA processing into mature 18S rRNA
[125]
, and also associates with and 
acts as a component of the 40S ribosomal small subunit where it assists with protein 
translation and synthesis
[183,184,185]
. Therefore, knockdown of LRP in this study could have 
interfered with ribosome formation and consequent translation of proteins that are critically 
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involved in proper cell functioning and survival, thereby leading to cell death. Additionally, it 
is suggested that ribosomes carry out translational processes in association with cytoskeletal 
components – in particular, tubulin[186]. Importantly, LRP/LR has been identified as a protein 
that tethers tubulin to the ribosome
[126,186]
 and thus, knockdown of this receptor in the present 
study may possibly be hampering this interaction – causing attenuated translation and 
resulting in cell death. Moreover, AsPC-1 cells exhibited a greater increase than IMR-32 cells 
in caspase-3 activity after siRNA-LAMR1 transfection. This observation strongly reiterates 
that LRP/LR is crucial in the maintenance of cellular viability, thus lower levels of LRP 
expression lead to increased levels of apoptotic induction and vice versa. The high correlation 
observed between the total levels of siRNA-LAMR1-mediated LRP knockdown and 
increases in caspase-3 activity in both of the cell lines under study firmly supports this 
suggestion. 
As previously stated, caspase-3 is an effector caspase meaning that it cleaves substrates in the 
cell in order to trigger the induction of apoptosis. Furthermore, caspase-3 is involved in both 
the intrinsic and extrinsic apoptotic pathways. Therefore, the observed increases in caspase-3 
activity after siRNA-LAMR1-mediated down-regulation of LRP can only be used as an 
indication of the occurrence of apoptosis. Caspase-8 and caspase-9 assays had to be 
additionally performed in order to assess which specific pathway is used by AsPC-1 and 
IMR-32 cells to undergo apoptosis after siRNA-LAMR1-mediated knockdown of LRP 
expression. It was observed that both of the tumourigenic cell lines exhibited increased 
caspase-8 activity after treatment with siRNA-LAMRI, when compared to non-transfected 
cells. Due to caspase-8 being critically involved in the death receptor (extrinsic) pathway as 
previously described, it can be said that siRNA-mediated LRP down-regulation induces 
apoptosis in AsPC-1 and IMR-32 cells via the extrinsic pathway.  
However, it was also observed that AsPC-1 cells treated with siRNA-LAMR1 exhibited 
significantly increased caspase-9 activity in comparison to non-transfected cells. Caspase-9 is 
intricately involved in the mitochondrial (intrinsic) pathway, thus suggesting that siRNA-
mediated LRP knockdown also induces apoptosis in AsPC-1 cells via the intrinsic pathway. 
One possible explanation of why siRNA-LAMR1 treated AsPC-1 cells undergo apoptosis via 
both the intrinsic and extrinsic pathways may be that these cells experience what is known as 
retaliatory caspase activation
[187,188]
 (Fig.40). This mechanism of caspase activation proposes 
that the two apoptotic pathways are able to activate each other using a feedback amplification 
loop
[187,188]
. Within this feedback loop, active caspase 9 is responsible for the cleavage and 
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activation of caspase-3, which in turn results in caspase-8 activation
[187,188]
. Therefore, this 
may possibly be the reason why increases in both caspase-8 and caspase-9 were observed in 
AsPC-1 cells after siRNA-mediated knockdown of LRP expression.   
 
Figure 40: The feedback amplification loop between the intrinsic and extrinsic apoptotic pathways. 
Active caspase-9 leads to the cleavage and subsequent activation of caspase-3, which then results in the 
activation of caspase-8. In this manner, certain cells to undergo apoptosis via both apoptotic pathways
[188]
.  
Apart from the cancerous cell lines pertaining to the present study, the occurrence of 
retaliatory activation of caspases has also been implicated in studies involving other cell lines 
and diseases.  One such study found that active caspase-8 effectively cleaved procaspase-3 
molecules in murine cells in response to TNFα crosslinking, subsequently forming active 
caspase-3 molecules, which in turn facilitated the activation of procaspase-9 molecules to 
form active caspase-9
[189]
. Another study suggested the involvement of the feedback 
amplification loop in the cells of the substantia nigra of mice infected with Parkinson’s 
disease – where a toxic component called MPTP induced caspase-9 activation in the 
substantia nigra cells, subsequently causing activation of caspase-3 which activated 
downstream caspase-8
[190]
. Additionally, research has suggested that activated caspase-8 
(formed by the action of Etoposide) interacts with the mitochondrial membrane in breast 
cancer (MDA-MB231) cells – leading to the generation of truncated Bid (t-Bid) which 
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promotes the release of cytochrome-c, ultimately resulting in caspase-9 and downstream 
caspase-3 activation within the afore-mentioned feedback loop
[191]
.  
Taken together, the results of the present study suggest that AsPC-1 cells undergo apoptosis 
via both the intrinsic and extrinsic pathways after siRNA-mediated LRP knockdown – 
possibly using the mechanism of retaliatory caspase activation. On the other hand, the 
findings propose that IMR-32 cells undergo apoptosis solely via the death receptor (extrinsic) 
pathway post siRNA-mediated LRP down-regulation, further evidenced by the absence of a 
significant increase in caspase-9 activity when compared to non-transfected cells. It could be 
speculated that since IMR-32 cells exhibit higher LRP/LR levels, there might be higher levels 
of interactions between LRP/LR and ECM components, particularly laminin. It may be 
possible that there is up-regulated expression and activation of collagenase due to the 
increased LRP/LR-laminin interaction
[192]
, and it may be worthwhile to examine whether 
collagenase somehow stimulates the death receptor pathway in neuroblastoma cells.  
5.7 LRP/LR as a target for cancer therapeutics 
Extensive research has implicated LRP/LR as a key contributor to the pathogenesis of viral 
diseases (such as Sindbis and Dengue), neurodegenerative diseases (such as Alzheimer’s 
disease), and of importance to the present study – cancer. Specifically, LRP/LR has been 
found to promote the tumourigenic phenotype and enhance tumour progression through its 
involvement in processes such as metastasis, tumour cell proliferation and angiogenesis, 
apoptotic evasion by tumour cells, and the maintenance of tumour cell viability. Due to the 
critical function of LRP/LR in tumourigenesis, the receptor can be deemed as a promising 
therapeutic target for the treatment of several cancer types. 
A vast array of in vitro studies targeting LRP/LR using anti-LRP/LR specific antibodies has 
been performed and have proved successful in the impediment of tumour- enhancing 
processes such as metastasis and angiogenesis. Additionally, the use of RNA interference 
technology to knockdown LRP expression has been observed as an effective means of 
hampering the maintenance of tumour cell viability – where siRNAs directed to LRP/LR of 
lung (A549), cervical (HeLa), liver (Hep3b), breast (MCF-7 and MDA-MB 231) and 
oesophageal (WHCO1) cancer cells all resulted in reduced viability of these tumourigenic 
cells as a consequence of siRNA-mediated reductions in total LRP/LR levels in all these cell 
lines. Similarly, the results of the present study suggest that siRNA-mediated down-
regulation of LRP expression significantly reduces the viability of pancreatic cancer (AsPC-
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1) and neuroblastoma (IMR-32) cells. Although past and present research suggests the high 
efficacy of siRNAs in reducing the viability of the afore-mentioned cell lines, it must be 
noted that each cancer type exhibits its own characteristic behaviour and therefore what holds 
true for one cancer type may not necessarily for other types of cancer. Hence, it is pivotal to 
test the use of LRP-specific siRNAs to a broad range of cancer types. 
Due to the integral physiological functions of LRP/LR in normal cells, such as cell migration, 
growth and differentiation, one prominent challenge that remains is the administration of 
siRNAs in vivo. Solely targeting LRP/LR in tumourigenic cells without compromising the 
function of normal cells is pivotal if therapeutic tools targeting LRP/LR are to be used.  
Nevertheless, in vitro studies have shown promising results that suggest siRNAs are effective 
as a therapeutic tool for certain cancers, making LRP/LR an attractive therapeutic target for 
cancer treatment. 
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK 
6.1 Conclusions 
The present study demonstrated that the siRNA-mediated knockdown of LRP expression 
significantly reduced the viability of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-
32) cells through hampering of cell proliferation and through the induction of apoptosis. 
Specifically, apoptosis occurred via both the intrinsic and extrinsic pathways in AsPC-1 cells 
likely due to feedback amplification loop entailing retaliatory caspase activation. Moreover, 
IMR-32 cells experienced apoptosis solely through the death receptor (extrinsic) pathway. 
These findings exemplify the critical role played by LRP/LR in the maintenance of cellular 
viability in both of these tumourigenic cell lines. Furthermore, specific siRNAs targeting LRP 
expression may be deemed as potential therapeutic tools for the treatment of pancreatic 
cancer and neuroblastoma.   
6.2 Future work 
As previously mentioned, all cancer types behave characteristically and differently from each 
other, and due to the fact that the present study only focused on pancreatic cancer and 
neuroblastoma, several other cancer types remain to be investigated with regards to siRNA-
mediated LRP down-regulation and cellular viability. Additionally, different cell lines within 
the same cancer type should be used to ensure that the observed effects are cancer-type 
specific and not just cell-line specific. Future studies could also consider making use of cell 
lines within a specific cancer type that are at different stages of their life cycle i.e early, 
middle and late stage cell lines in order to establish at which stage siRNA-mediated LRP 
knockdown is most effective at reducing cellular viability. Furthermore, time and dose-
dependent studies could also be carried out in order to determine optimal transfection periods 
and siRNA dosages.  
Due to LRP/LR playing several physiological roles in normal cells, it may be worthwhile to 
investigate the effect of siRNA-mediated LRP down-regulation on normal cells. In the event 
that this knockdown of LRP exerts little or no effect on the functioning of normal cells, 
further studies could entail the use of animal models such as nude mice to gain insight into in 
vivo siRNA administration. Nude mice are favourable animal models since they possess the 
ability to receive several types of tumour tissue grafts without exhibiting a rejection response 
or immune defence mechanisms towards these grafts
[193]
. Animal trials may possibly lead to 
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clinical trials, thereby allowing the effect of siRNA-mediated LRP down-regulation to be 
assessed in the human body. Furthermore, future studies could explore the use of siRNAs in 
conjunction with anti-LRP/LR specific antibodies to treat several tumour-promoting 
processes at the same time. 
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APPENDIX A 
 
General – Suppliers list: 
 Media (RPMI and EMEM), BSA, de-ionized water, molecular weight marker – 
Thermo Scientific 
 L-glutamine, HEPES, sodium pyruvate, non-essential amino acids, 
penicillin/streptomycin, FCS, trypsin, BCA reagents , APS, acrylamide, TEMED, 
paraformaldehyde, PCA, MTT, fluoromount mounting fluid, SDS– Sigma Aldrich 
 PBS – Gibco by Life Technologies 
 DMSO, lysis buffer, Tween – Merck Millipore 
 Methanol – VWR chemicals 
 PVDF membrane – Pall corporation 
 Chemiluminescent substrate - Biorad 
 Microscopy slides and coverslips – Labocare 
 24-well, 6-well and 6cm plates – Corning Inc. 
 
Antibodies and siRNAs – Suppliers list: 
 IgG1-iS18 – Affimed Therapeutics 
 Anti-human IgG-HRP, anti-human PE, anti-rabbit APC– Abcam 
 Anti-β actin peroxidase, anti-CAT, Hoescht 33342, esiRNA-RPSA, esiRNA-RLUC – 
Sigma 
 Lipofectamine transfection reagent – Invitrogen by Life Technologies 
 siRNA-LAMR1 (2nmol), siRNA-scr (5nmol), DharmaFect1 transfection reagent – 
Dharmacon 
 5x siRNA reconstitution buffer – Thermo Scientific   
 
Kits – suppliers list: 
 BrdU assay kit- Calbiochem 
 Annexin V-FITC/ 7-AAD kit – Beckman Coulter 
 Caspase 3,-8 and -9 kits – Abcam 
 
Equipment list: 
 Flow cytometer – BD Accuri C6 
 Confocal microscope – Zeiss LSM 710 3-channel (images were captured using the 
blue laser, 63X magnification, and using Zen 2011 software). 
 Laminar flow – Labotec 
 ELISA reader – Tecan (using Magellan software) 
 Centrifuge – Eppendorf 5417C 
 Pipettes and micropipettes – Eppendorf research 
 Gel casting and running apparatus – Biorad 
 pH meter – Eutech instruments 
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Transfection procedure using siRNA-LAMR1 and siRNA-scr: 
Pellets of siRNA-LAMR1 (2nmol) were reconstituted in 200µl of 1X siRNA buffer, and 
siRNA-scr (5nmol) was reconstituted in 500µl of 1X siRNA buffer before use. The table 
below shows amounts of siRNA and corresponding components used for transfections per 
well of a 6-well, 24-well and 96-well plate. 
 6-well plate 24-well plate 96-well plate 
Serum-free media 
(µl) – for addition of 
siRNA 
195 48.74 12.19 
Reconstituted 
siRNA-LAMR1 or 
siRNA-scr (µl)  
5 1.25 0.31 
Serum-free media 
(µl) – for addition of 
DharmaFect1 
transfection reagent 
190 47.5 11.89 
DharmaFect1 (µl) 10 2.5 0.63 
Antibiotic free media 1600 400 100 
 
Basic procedure:  
Add reconstituted siRNA-LAMR1 or siRNA-scr to the corresponding volume of serum-free 
media in an Eppendorf tube. In a second Eppendorf tube, add transfection reagent to the 
corresponding volume of serum-free media. Incubate both tubes for 5 minutes at room 
temperature and then mix the contents of both tubes together. Incubate for a further 20 
minutes at room temperature before adding to suggested volumes of antibiotic-free media. 
Thereafter, the resultant siRNA solution may be added to the cells. 
 
Transfection procedure using esiRNA-RPSA and esiRNA-RLUC: 
esiRNA-RPSA and esiRNA-RLUC are purchased reconstituted. The table below shows 
volumes of esiRNA and corresponding components used for transfections per well of a 6-
well, 24-well and 96-well plate. 
 6-well plate 24-well plate 96-well plate 
Opti-MEM media – 
for addition of 
esiRNA (µl) 
125 25 6.25 
esiRNA-RPSA or 
esiRNA-RLUC (µl) 
5 1.25 0.31 
Opti-MEM media – 
for addition of 
Lipofectamine 
transfection reagent 
(µl) 
125 25 6.25 
Lipofectamine (µl) 5 1.25 0.31 
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Basic procedure:  
Add esiRNA-RPSA or esiRNA-RLUC to the corresponding volume of Opti-MEM media in 
an Eppendorf tube. In a second Eppendorf tube, add transfection reagent to the corresponding 
volume of Opti-MEM media. Incubate both tubes for 5 minutes at room temperature and then 
mix the contents of both tubes together. Thereafter, the resultant siRNA solution may be 
added to the cells. 
 
Composition of 12% polyacrylamide gels (per gel): 
 Separating gel Stacking gel 
Distilled water 2.15ml 1.83ml 
40% acrylamide 1.5ml 313µl 
Separating Tris buffer 1.25ml - 
Stacking Tris buffer - 313µl 
10% SDS 50µl 25µl 
APS 50µl 25µl 
TEMED 2µl 2.5µl 
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